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Introduction {#sec1}
============

The MYC oncoprotein is a transcription factor that regulates broad programs of gene expression, promoting cell proliferation and cell growth and inducing major changes in growth-associated processes such as cellular metabolism and the interaction of cells with the micro-environment ([@bib23], [@bib52]). MYC proteins are almost universally present at active core promoters. Proteomic analyses show that MYC and its paralog MYCN affect the function of RNA polymerase II (RNAPII) via multiple distinct protein complexes ([@bib3], [@bib8], [@bib45]). MYC proteins can enhance recruitment of RNAPII to promoters ([@bib27]), promoter escape ([@bib8]), release of RNAPII from the pause site ([@bib76], [@bib91]), and RNAPII processivity during elongation ([@bib3]). MYCN can suppress the accumulation of promoter-proximal R-loops and the recruitment of mRNA de-capping complexes, which terminate transcription at the pause site ([@bib7], [@bib38]).

Cells and tumors expressing deregulated levels of MYC rely on a number of specific factors for survival, including an enhanced dependence on anti-apoptotic proteins and trophic signals ([@bib71]), on glutamine as a nutrient source ([@bib32], [@bib94]), on splicing factors ([@bib40]), on cyclin-dependent kinases ([@bib13], [@bib15], [@bib41]), and on AMP-dependent kinase (AMPK), which is activated by an increase in cellular AMP levels ([@bib47], [@bib58]). The analysis of these dependencies has produced critical insights into the process of MYC-driven oncogenic transformation and led to new approaches to selectively eradicate MYC-driven tumor cells for therapy ([@bib24], [@bib36]). Cells expressing deregulated levels of MYC also depend on the AMPK-related kinase NUAK1 (also known as ARK5, AMPK-related kinase 5) ([@bib58], [@bib62]). Likewise, colon tumors, which express high MYC levels because of loss-of-function mutations in the APC tumor suppressor gene, depend on NUAK1 for tumor growth and maintenance ([@bib72]). Several explanations have been put forward to explain this dependence; for example, NUAK1 has been linked to cellular energy metabolism ([@bib58]), to p53 function ([@bib39]), and to responses to oxidative stress ([@bib72]), which affect the nuclear localization of NUAK1 ([@bib69]). Nevertheless, the biochemical processes that establish the dependence of MYC-overexpressing cells on NUAK1 are not as clear as for the other dependencies described above.

A well-established function of NUAK1 is to control the activity of protein phosphatase 1 (PP1) ([@bib96]). PP1 holoenzymes consist of a broadly active catalytic core (encoded by one of three highly homologous genes: *PPP1CA*, *PPP1CB*, or *PPP1CC*) and one of many regulatory subunits ([@bib89]). Regulatory subunits can both target the PP1 holoenzyme to specific compartments in a cell and control its catalytic activity (e.g., some subunits inhibit PP1 activity toward specific substrates) ([@bib89]). In the cytoplasm, a major regulatory subunit of PP1 is MYPT1 (myosin phosphatase target subunit 1, encoded by the gene *PPP1R12A*), which regulates the interaction of actin and myosin ([@bib60]). NUAK1 directly interacts with PPP1CB and forms a trimeric complex with PPP1CB and MYPT1. In the trimer, NUAK1 phosphorylates MYPT1 and promotes association of MYPT1 with 14-3-3 proteins ([@bib96]). This reaction blocks the interaction of MYPT1 and PP1 with myosin light-chain kinase (MLC2), increases phosphorylation of MLC2, and thereby activates myosin II. The MYPT1/NUAK1 interplay also regulates the activity of Polo-like kinase (PLK1) throughout the cell cycle ([@bib5], [@bib92]) and controls AKT-dependent phosphorylation of GSK3β ([@bib72]). Whether NUAK1 has similar roles on other PP1 holoenzymes in a cell is unknown.

Here we show that NUAK1 complexes with PP1 in the nucleus and promotes spliceosome activity. NUAK1 and PP1 are involved in a regulatory circuit that couples transcriptional elongation to spliceosome activity. Deregulated expression of MYC overrides this control, providing a mechanistic model why tumor cells with high MYC levels depend on NUAK1.

Results {#sec2}
=======

NUAK1 Binds to Chromatin and Interacts with a Nuclear PP1 Network {#sec2.1}
-----------------------------------------------------------------

Previous studies have shown that NUAK1 associates with PP1 complexes and have identified the cytoplasmic PP1 regulatory subunit MYPT1 as a major interaction partner of NUAK1 ([@bib96]). Surprisingly, however, endogenous NUAK1 localized mainly to the nucleus of U2OS osteosarcoma cells; the staining occurred in a speckled pattern that partly co-localized with the nuclear pool of the protein phosphatase catalytic subunit beta (PPP1CB) ([Figure 1](#fig1){ref-type="fig"}A). NUAK1 was also localized mainly in the nucleus in a panel of additional cell lines that we analyzed ([Figure S1](#mmc1){ref-type="supplementary-material"}A), consistent with a recent study ([@bib69]). Fractionation experiments showed that a significant fraction of both NUAK1 and PPP1CB was bound to chromatin ([Figure 1](#fig1){ref-type="fig"}B). To exclude that this staining reflected a cross-reactivity of the antibody, we stably expressed HA-tagged NUAK1 in U2OS and MCF10A cells (HA-NUAK1). Like its endogenous counterpart, the bulk of HA-NUAK1 localized to the cell nucleus and bound to chromatin ([Figures 1](#fig1){ref-type="fig"}C, 1D, and [S1](#mmc1){ref-type="supplementary-material"}B). Staining of control cells infected with empty vectors confirmed the specificity of staining ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Parallel immunostaining confirmed that MYPT1 is localized mainly in the cytoplasm of U2OS cells ([Figure 1](#fig1){ref-type="fig"}C).Figure 1NUAK1 Binds to Chromatin and Interacts with a Nuclear PP1 Network(A) U2OS cells stained for endogenous NUAK1 and PPP1CB. DAPI is used as nuclear counterstain (n = 3; in all legends, n indicates the number of independent biological replicates).(B) Immunoblot of fractionation of U2OS cells probed with the indicated antibodies. Ten percent of cytoplasm and nucleoplasm fractions were loaded. RNAPII (chromatin) and TUBA1A (cytoplasm) were used as localization controls (n = 3).(C) Immunofluorescence of U2OS cells stably expressing HA-tagged NUAK1 stained with α-HA and α-MYPT1 antibodies (n = 3).(D) Cell fractionation of U2OS cells stably expressing HA-tagged NUAK1. Ten percent of cytoplasm and nucleoplasm fractions were loaded. RNAPII and TUBA1A were used as controls (n = 3).(E) Mass spectrometry (MS) analysis of FLAG-NUAK1 co-immunoprecipitates (IP) from U2OS cells expressing amino-(NT-IP)- or carboxy-(CT-IP)-terminally-FLAG-tagged NUAK1. Proteins are sorted according to log~2~ fold enrichment over IP performed in U2OS cells expressing empty vector (EV). Dot size is according to number of peptides identified by MS (n = 2).(F) Venn diagram of NUAK1 interactors and previously documented PP1 interaction partners (BioGrid database).(G) List of the 14 PP1 interactors from (F). Nuclear (green) or cytoplasmic (gray) localization is shown.(H) List of selected GO terms enriched by analyzing proteins enriched in both NT- and CT-IP (n = 154). Terms referring to nuclear protein, splicing factors, or PP1 interactors are shown. FDR, false discovery rate; fold enr., fold enrichment.(I) Proximity ligation assay (PLA) in U2OS cells documenting proximity of SF3B1 and NUAK1 or PNUTS. Red dots indicate proximity of the indicated proteins. DAPI is used as nuclear counterstain.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To identify nuclear interaction partners of NUAK1, we immunoprecipitated cell lysates of U2OS cells stably expressing either N-terminally or C-terminally FLAG-tagged NUAK1 with antibodies directed against the FLAG tag. Control immunoprecipitations showed that both amino-terminally and C-terminally tagged NUAK1 efficiently co-precipitated MYPT1 as well as PPP1CB ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Mass spectrometry of recovered complexes revealed that immunoprecipitations using an anti-FLAG antibody from either cell line enriched for a virtually identical set of proteins relative to control immunoprecipitations from empty vector-infected cells ([Figure 1](#fig1){ref-type="fig"}E). Gene Ontology (GO) term analyses and comparison with a protein interaction database showed that the immunoprecipitates were significantly enriched for protein phosphatase complexes and contained multiple known interactors of PP1, the majority of which localizes to the nucleus ([Figures 1](#fig1){ref-type="fig"}F--1H and [S1](#mmc1){ref-type="supplementary-material"}D). In addition, NUAK1 associated with multiple proteins involved in mRNA splicing ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Specifically, components of the U2 and U12 spliceosomal small nuclear ribonucleoprotein particle (snRNP) complexes, which mediate the recognition of the splicing branching point on pre-mRNA, as well as the Prp19 complex and the methylosome, which are involved in spliceosome assembly, were enriched in the immunoprecipitates ([Figure 1](#fig1){ref-type="fig"}H) ([@bib10], [@bib16], [@bib25]). Consistently, immunofluorescence showed that the speckled pattern of NUAK1 co-localized to a significant degree with the spliceosomal protein SC35 (encoded by *SRSF2*), a typical nuclear speckle marker ([@bib35]) ([Figure S1](#mmc1){ref-type="supplementary-material"}E), and proximity ligation assay (PLA) showed that NUAK1 interacts with SF3B1 ([Figure 1](#fig1){ref-type="fig"}I). We have recently characterized the RNAPII and MYC interactomes, both of which contain multiple proteins involved in transcription and RNA processing ([@bib3]). The overlap of the NUAK1 interactome with either the RNAPII or MYC interactome was limited to a small number of proteins ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Notably, a nuclear PP1 regulatory subunit, PNUTS, that was previously found to interact with RNAPII ([@bib17]), was also found in the NUAK1 interactome (see below) and interacted with SF3B1 in PLA assays ([Figure 1](#fig1){ref-type="fig"}I). We therefore explored further the interaction of NUAK1 with nuclear PP1 complexes.

PNUTS Interacts with and Is Phosphorylated by NUAK1 in the Nucleus {#sec2.2}
------------------------------------------------------------------

In the cytoplasm, NUAK1 controls the function of PP1 holoenzymes by phosphorylating the MYPT1 regulatory subunit, thereby altering its function and localization ([@bib96]). In the nucleus, the catalytic subunit of PP1 interacts with one of three major subunits: Repo-Man (encoded by the *CDCA2* gene), PNUTS (PP1-nuclear targeting subunit, encoded by *PPP1R10*), and NIPP1 (nuclear inhibitor of PP1, encoded by *PPP1R8*) ([@bib90]). Of those, PNUTS, but neither Repo-Man nor NIPP1, was present in NUAK1 interactome ([Figures 1](#fig1){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}D). This was confirmed by co-immunoprecipitation of PNUTS and HA-NUAK1 ([Figure 2](#fig2){ref-type="fig"}A). PLAs showed that NUAK1 and PNUTS interacted in the nucleus, whereas NUAK1 and MYPT1 interacted mainly in the cytoplasm ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). Like NUAK1 and PPP1CB, the bulk of PNUTS was bound to chromatin ([Figures 1](#fig1){ref-type="fig"}B and 1D), and like NUAK1, PNUTS interacted with SF3B1 in PLA assays ([Figure 1](#fig1){ref-type="fig"}I). NUAK1 interacts directly with the catalytic subunit of PP1 holoenzymes via a conserved four amino acid motif (GILK) ([@bib96]) ([Figure 2](#fig2){ref-type="fig"}C). Consistently, incubation of cells with a corresponding peptide abolished the interaction of NUAK1 with both PPP1CB and PNUTS, as documented by PLAs ([Figure 2](#fig2){ref-type="fig"}D). Intriguingly, a phosphoproteomic analysis of NUAK1-depleted cells (see below) showed that serine 313 of PNUTS is a potential target site of NUAK1. To confirm this hypothesis, we raised a phospho-specific antibody against this site. Immunoblots of lysates of transfected cells confirmed that the antibody recognizes wild-type PNUTS, but neither S313A, S313D, nor S313E mutant PNUTS expressed at equal levels ([Figure 2](#fig2){ref-type="fig"}E). Depletion of NUAK1 using three different short hairpin RNAs (shRNAs) ([Figure 2](#fig2){ref-type="fig"}F) or a small interfering RNA (siRNA) ([Figure S2](#mmc1){ref-type="supplementary-material"}B) decreased phosphorylation of endogenous PNUTS at S313 but had no effect on total PNUTS levels. We concluded that NUAK1 interacts with nuclear PNUTS/PPP1CB complexes and phosphorylates PNUTS on S313.Figure 2PNUTS Interacts with and Is Phosphorylated by NUAK1 in the Nucleus(A) Immunoblot of α-HA immunoprecipitates of U2OS cells expressing HA-tagged NUAK1 or empty vector (EV). Input corresponds to 1% lysate (n = 3).(B) Proximity ligation assay (PLA) performed in U2OS cells expressing HA-tagged NUAK1 or EV (used as negative control). Red dots indicate proximity of the indicated proteins. DAPI is used as nuclear counterstain (n = 3).(C) Cartoon depicting the mode of interaction of NUAK1 with MYPT1 and the suggested mode of interaction with PNUTS. Binding motifs of NUAK1 (GILK) and MYPT1/PNUTS (RVxF) to PP1 are also depicted. Yellow circle, phosphorylation.(D) PLA performed in U2OS cells expressing HA-tagged NUAK1 or EV (used as negative control). Cells were treated for 3 h with 50 μM GILK or control peptide. Red dots indicate proximity of the indicated proteins. DAPI is used as nuclear counterstain (n = 3).(E) Immunoblot using the indicated antibodies of U2OS cells transfected with pcDNA3 vectors encoding HA-tagged rat wild-type or S313A/D/E-mutated PNUTS; EV was used as negative control. In the α-pS313-PNUTS panel, the upper band represents endogenous PNUTS, while the lower is the exogenous rat protein. VCL was used as loading control (n = 3).(F) U2OS cells were infected with three independent doxycycline (DOX)-inducible shRNAs targeting *NUAK1* and, where indicated, treated with DOX (1 μg/mL) for 24 h. Asterisk denotes unspecific band (n = 3). Bottom: immunoblot of NUAK1 confirming its depletion. VCL was used as loading control (n = 3).(G) Volcano plot showing differentially regulated phosphosites and the functional annotation of respective proteins in a spike-in SILAC phosphoproteomic analysis upon transfection of a siRNA pool targeting *NUAK1* mRNA (siNUAK1). Significance is indicated by the dashed line (p \< 0.05) (n = 3).(H) Waterfall plot showing differentially spike-in SILAC-labeled phosphorylated residues (p \< 0.05) upon NUAK1 depletion. Orange, phosphosites of PP1-interacting proteins (n = 3).(I) Differentially phosphorylated residues upon NUAK1 depletion (n = 197, p \< 0.05) were used as input for a GO term analysis (left: cell component; right: biological function). FDR, false discovery rate; fold enr., fold enrichment.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Regulatory subunits such as PNUTS can either target PP1 catalytic subunits to specific sites or inhibit PP1 activity at specific subcellular localizations ([@bib89]). To determine how NUAK1 affects PP1 activity, we performed phosphoproteomic analyses of NUAK1-depleted U2OS cells. The analysis showed that siRNA-mediated depletion of NUAK1 altered the phosphorylation of a large set of nuclear proteins ([Figure 2](#fig2){ref-type="fig"}G). Specifically, depletion of NUAK1 downregulated phosphorylation of many proteins that interact with PP1, suggesting that NUAK1 inhibits their dephosphorylation ([Figure 2](#fig2){ref-type="fig"}H). A GO term analysis showed that differentially phosphorylated proteins are broadly involved in RNA processing ([Figure 2](#fig2){ref-type="fig"}I). In line with the function of proteins identified in the NUAK1 interactome, a subset of differentially phosphorylated proteins is involved in RNA processing and splicing; this includes, for example, SRRM2, a protein identified as a strong NUAK1 interactor ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Finally, depletion of NUAK1 also altered the phosphorylation of multiple proteins not found in the PP1 interactome, arguing that NUAK1 also has PP1-independent effects and that some changes in the phosphoproteome are indirect. We concluded that NUAK1 associates with nuclear PP1 holoenzymes and the spliceosome and is required for phosphorylation of multiple proteins involved in RNA processing.

PNUTS Binds Chromatin via RNA and Promotes Spliceosome Activity {#sec2.3}
---------------------------------------------------------------

To better understand how PNUTS, PPP1CB, and NUAK1 interact with chromatin, we performed fractionation experiments upon treatment of nuclear extracts with RNase A, which discriminates resident chromatin proteins from proteins that interact with chromatin indirectly via RNA. As expected, treatment with RNase A released a significant fraction of the splicing factor SF3B1 and the spliceosome-associated NIPP1 protein from chromatin, while actively transcribing (phosphorylated) RNAPII or histone H2B remained bound to chromatin ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Intriguingly, RNase A released a significant fraction of PNUTS and PPP1CB from chromatin, arguing that both proteins are bound to chromatin at least in part via association with RNA ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). In contrast, RNase A treatment did not affect chromatin association of NUAK1 ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A).Figure 3PNUTS Binds Chromatin via RNA and Promotes Spliceosome Activity(A) Immunoblot documenting chromatin association of the indicated proteins in control cell lysates and in lysates upon RNase A treatment. Cell fractionation was performed on U2OS cells expressing HA-tagged NUAK1. Nucleopl., nucleoplasmic fraction; chromatin, chromatin-bound fraction. SF3B1 and NIPP1 or phosphorylated RNAPII and H2B were used as RNA- and chromatin-bound controls, respectively (n = 3).(B) Expression of PNUTS-bound genes (n = 2,786) versus all expressed genes (n = 19,382). The p value was calculated with a two-tailed Wilcoxon rank-sum test. CPM, counts per million.(C) Genome Browser tracks showing PNUTS, phospho-S313-PNUTS (pPNUTS), and RNAPII binding to representative genes. Input tracks are included as control.(D) Average density plots of PNUTS ChIP-seq (left y axis) and pPNUTS ChIP-RX (right y axis). The shadow around tracks indicates SEM. TSS, transcription start site.(E) Average density plots of PNUTS ChIP-seq (left y axis) and pPNUTS ChIP-RX (right y axis) centered to transcription end site (TES). The shadow around tracks indicates SEM.(F) PNUTS ChIP performed upon RNase A treatment. IgG ChIP was used as antibody specificity control. TSS, transcription start site; 3′RT, 3′ readthrough site; neg ct, negative control (mean ± SD of technical triplicates of a representative experiment; n = 3).(G) Immunoblots documenting phosphorylation of SF3B1 at the indicated sites. U2OS cells were transfected with a siRNA pool targeting PNUTS and, 48 h later, treated with 25 nM calyculin A for 30 min. ACTB was used as loading control (n = 3).See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

The dependence of chromatin association of PNUTS on RNA is consistent with the presence of an RNA-binding domain in PNUTS and with previous observations that long noncoding RNA (lncRNA) molecules can target PNUTS to specific genes and that PNUTS binds nascent RNA ([@bib6], [@bib48], [@bib95]). To determine the sites on chromatin to which PNUTS is bound in an unbiased manner, we performed chromatin immunoprecipitation followed by sequencing (ChIP-seq). A correlation of ChIP-seq data with RNA sequencing (RNA-seq) data showed that PNUTS-bound genes display relatively high levels of expression but did not reveal a significant enrichment of specific functional categories of PNUTS-bound genes ([Figure 3](#fig3){ref-type="fig"}B). Importantly, ChIP-seq showed that PNUTS bound both downstream of the transcription start site (TSS) of 2,571 genes and close to the transcription end site (TES) at 584 genes, as demonstrated both by inspection of multiple individual genes and global analyses ([Figures 3](#fig3){ref-type="fig"}C--3E). PNUTS binding downstream of the TSS peaked around the RNAPII pause site and both immediately 5′ and 3′ of the first exon-intron boundary ([Figure 3](#fig3){ref-type="fig"}D). Previous observations have implicated PNUTS in transcription termination ([@bib2], [@bib18]). Consistently, a major PNUTS peak was observed around the TES ([Figures 3](#fig3){ref-type="fig"}C and 3E). Our analysis also confirmed previous observations that PNUTS avidly binds histone clusters ([Figure S3](#mmc1){ref-type="supplementary-material"}B) ([@bib90]). ChIP-seq with exogenous reference genome spike-in (ChIP-RX) using the phospho-specific antibody showed that chromatin association of phosphorylated pS313-PNUTS closely resembled that of total PNUTS ([Figures 3](#fig3){ref-type="fig"}C--3E). ChIP experiments upon RNase A confirmed that PNUTS bound to both promoter-proximal and TES in part via interaction with RNA ([Figure 3](#fig3){ref-type="fig"}F). Consistent with the observation that PNUTS is part of the interactome of newly transcribed RNA ([@bib6]), treatment of cells with flavopiridol (FP), an inhibitor of the CDK9 kinase that globally blocks nascent RNA synthesis, attenuated PNUTS chromatin binding ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}C). We concluded that PNUTS binds chromatin in part via association with nascent RNA.

The localization of PNUTS binding, its dependency on RNA, and the co-precipitation of PNUTS with spliceosomal proteins suggested that PNUTS has a role in splicing. Indeed, PP1 activity affects the phosphorylation status of several splicing factors, thereby regulating both spliceosome assembly and its catalytic cycle ([@bib1], [@bib85]). To test this hypothesis, we used two phospho-specific antibodies that recognize phosphorylated T313 and T328 in the TP-rich domain of SF3B1 ([Figure S3](#mmc1){ref-type="supplementary-material"}E); these residues are phosphorylated exclusively in catalytically active spliceosomes ([@bib35]). Indeed, the U2 spliceosome component SF3B1 is a well-described PP1 target, which is hyperphosphorylated during the first step of catalysis and dephosphorylated during the second one ([@bib35], [@bib85], [@bib87]). Depletion of PNUTS strongly reduced phosphorylation at both sites and inhibition of PP1 using the phosphatase inhibitors calyculin A and okadaic acid (which target both PP1 and PP2A phosphatases) reverted the inhibition ([Figures 3](#fig3){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}D). Collectively, the data indicate that PNUTS locally inhibits PP1 downstream of the TSS of actively transcribed genes to promote spliceosome activity.

NUAK1 Controls Chromatin Association of PNUTS {#sec2.4}
---------------------------------------------

To understand whether NUAK1 affects PNUTS function, we incubated U2OS cells with the GILK peptide that blocks NUAK1 interaction with PP1 and found that this led to a strong decrease in SF3B1 phosphorylation ([Figure 4](#fig4){ref-type="fig"}A), indicating that NUAK1 or a structurally related kinase is required for spliceosome activity. Consistently, both shRNA- and siRNA-mediated depletion of NUAK1 reduced SF3B1 phosphorylation at T313 and T328, although the effects were not as strong as with the GILK peptide ([Figures 4](#fig4){ref-type="fig"}B and 4C). We reasoned that this might be due to the relatively slow kinetics of a depletion experiment, which might allow cells to adapt to a decrease in NUAK1 activity. To test this hypothesis, we used two chemically distinct small molecules to acutely inhibit NUAK1. The first is BAY-880, which we identified as a potent inhibitor of NUAK1 that inhibits 96% of its kinase activity at 1 μM concentration ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B; [Table S1](#mmc1){ref-type="supplementary-material"}). Testing BAY-880 against a panel of 274 kinases showed that NUAK1 is the best target and identified a small number of additional kinases that may be inhibited by this compound ([Figure S4](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc1){ref-type="supplementary-material"}). Consistent with this, a phosphoproteomic analysis showed that the changes in phosphorylation induced by siRNA-mediated depletion of NUAK1 in U2OS cells showed a statistically highly significant overlap with changes induced by BAY-880 ([Figure 4](#fig4){ref-type="fig"}D; p = 1.5 × 10^−13^), and a GO term analysis of changes of differentially regulated phosphosites showed that processes targeted by BAY-880 highly overlapped with the ones targeted by depletion of NUAK1 ([Figure 4](#fig4){ref-type="fig"}D). Importantly, both depletion of NUAK1 and BAY-880 jointly targeted multiple proteins involved in RNA metabolism and, specifically, RNA splicing, 3′ end processing, and localization ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}C). In addition, we used a well-characterized NUAK1 inhibitor, HTH-01-015 ([@bib4]). Notably, potential off-target activities of BAY-880 greatly differed from those of HTH-01-015, arguing that joint targets of both inhibitors reflect on-target effects resulting from NUAK1 inhibition ([Figure S4](#mmc1){ref-type="supplementary-material"}B). We therefore confirmed that both compounds decrease phosphorylation of S313-PNUTS and observed that BAY-880 was more potent than HTH-01-015 in inhibiting NUAK1 activity ([Figures 4](#fig4){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}D). Phosphoproteomic analyses showed that acute inhibition by either inhibitor targeted highly overlapping sets of RNA-processing proteins, as observed in response to depletion of NUAK1 ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4G; compare with [Figure S4](#mmc1){ref-type="supplementary-material"}C). A potentially relevant off-target activity of BAY-880 is inhibition of CDK9; also, PNUTS has been implicated in the phosphorylation of the CTD of RNAPII at serine 5 ([@bib17]). However, both BAY-880 and HTH-01-015 had only minor effects on S2- or S5-RNAPII phosphorylation, while the CDK9 inhibitors FP and LDC00067 or inhibitors of other transcription-associated CDKs essentially abolished phosphorylation at S2 ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Furthermore, comparison of the phosphosites identified by phosphoproteomics upon BAY-880 or siRNA-mediated depletion of NUAK1 with recently described CDK9 targets ([@bib82]) showed only a statistically nonsignificant overlap ([Figure S5](#mmc1){ref-type="supplementary-material"}B). We concluded that the effects of both drugs are not mediated via inhibition of CDK9 and that NUAK1 has no direct role in RNAPII phosphorylation. Both NUAK1 inhibitors reduced phosphorylation of SF3B1 at the sites that indicate spliceosome activity; the decrease in phosphorylation was stronger in response to BAY-880, correlating with the stronger inhibition of NUAK1-dependent phosphorylation of S313-PNUTS ([Figure 4](#fig4){ref-type="fig"}E).Figure 4NUAK1 Controls Chromatin Association of PNUTS(A) Immunoblots documenting phosphorylation of SF3B1 at the indicated sites. U2OS cells were treated 4 h with 50 μM GILK (or control \[CT\]) peptide. ACTB was used as loading control (n = 3).(B) Immunoblots documenting phosphorylation of SF3B1 at the indicated sites. U2OS cells stably expressing a doxycycline (DOX)-inducible shRNA targeting *NUAK1* mRNA (shNUAK1 \#3 in [Figure 2](#fig2){ref-type="fig"}F) was induced with DOX for 24 h. ACTB was used as loading control (n = 3).(C) Same as B, but using and siRNA pool targeting NUAK1 (siNUAK1) or control siRNA pool. ACTB was used as loading control (n = 3).(D) Left: Venn diagram showing the overlap between significantly differentially regulated phosphosites identified in response to siRNA-mediated NUAK1 depletion (48 h) or treatment with 10 μM BAY-880 (2 h) in a TMT phosphoproteomic experiment. Right: GO term analysis of differentially phosphorylated proteins. At the top is a Venn diagram showing the overlap between all identified GO terms; below is a pie chart of categories of 48 RNA-related GO terms.(E) Immunoblots documenting phosphorylation of PNUTS at S313 and of SF3B1 at the indicated sites after 24 h incubation of U2OS cells with the indicated concentrations of BAY-880 or HTH-01-015. ACTB was used as loading control (n = 3).(F) Read density plot analysis of PNUTS ChIP-seq upon 4 h 10 μM BAY-880 treatment (n = 3,172 PNUTS-bound genes). The shadow around tracks indicates SEM. TSS, transcription start site; TES, transcription end site.(G) Genome Browser track at the *TPM1* gene of PNUTS ChIP-seq and phospho-S313-PNUTS (pPNUTS) ChIP-RX from U2OS cells treated 4 h with 10 μM BAY-880. Input tracks are included as control.(H) ChIP experiments using an α-HA antibody showing chromatin association of wild-type PNUTS and of PNUTS S313A after transfection in U2OS cells of expression plasmids encoding HA-tagged PNUTS or empty vector (EV). IgG ChIP was used as antibody specificity control. TSS, transcription start site; 3′RT, 3′ readthrough site; neg ct, negative control (mean ± SD of technical triplicates of a representative experiment; n = 3).(I) Immunoblots documenting phosphorylation of SF3B1 at the indicated sites after treatment of U2OS cells with 10 μM BAY-880 or 1 μM pladienolide B (PlaB) for 4 h. VCL was used as loading control. Quantification of T313- and T328-SF3B1 bands was compared with DMSO-treated samples and normalized to VCL band intensity from three independent experiments.See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

PNUTS ChIP-seq and pS313-PNUTS ChIP-RX showed that chromatin association both at TSS and TES was strongly reduced by inhibition of NUAK1 ([Figures 4](#fig4){ref-type="fig"}F, 4G, and [S5](#mmc1){ref-type="supplementary-material"}C). Comparison of chromatin binding of wild-type PNUTS with S313A-mutated PNUTS showed that this decrease was due partly to the decreased phosphorylation at this site, but the magnitude in the decrease observed after NUAK1 inhibition revealed that other events (e.g., changes in spliceosomal proteins) contribute to the decrease in association ([Figure 4](#fig4){ref-type="fig"}H). In contrast, S313A-PNUTS showed no difference to wild-type PNUTS in terms of binding to PP1 and nuclear localization (not shown). Finally, BAY-880 effect on splicing activity was compared with that of pladienolide B (PlaB), a well-characterized splicing inhibitor ([@bib44], [@bib51]). PlaB abolished SF3B1 phosphorylation, while BAY-880 inhibited SF3B1 phosphorylation by 50%--70%. ([Figures 4](#fig4){ref-type="fig"}I and [S5](#mmc1){ref-type="supplementary-material"}D). Notably, PlaB did not affect S313-PNUTS phosphorylation, confirming that PlaB activity on SF3B1 is PNUTS-independent ([Figure S5](#mmc1){ref-type="supplementary-material"}D) ([@bib51]). Interestingly, dephosphorylation of S313 upon NUAK1 inhibition by either BAY-880 or HTH 01-015 was essentially complete within 1 h treatment ([Figure S5](#mmc1){ref-type="supplementary-material"}D), suggesting that the effects of the inhibitors on PNUTS or SF3B1 phosphorylation are direct. We concluded that phosphorylation by NUAK1 promotes chromatin association of PNUTS and spliceosome activity.

NUAK1 Promotes Splicing and Transcription Termination {#sec2.5}
-----------------------------------------------------

To determine whether NUAK1 is required for co-transcriptional splicing, we labeled nascent RNA using a pulse of 15 min with 4-thiouridine (4sU) and sequenced labeled RNA either immediately (pulse) or 2 h after 4sU withdrawal (chase; [Figure S5](#mmc1){ref-type="supplementary-material"}E). The experiment was performed in control (DMSO) cells as well as in the presence of BAY-880 or PlaB. As expected, the percentage of exonic and spliced reads strongly increased during the chase, reflecting processing of pre-mRNA ([Figure 5](#fig5){ref-type="fig"}A). PlaB blocked the increase in exonic and spliced reads and caused a marked increase in intronic reads, indicating that PlaB blocked splicing ([Figure 5](#fig5){ref-type="fig"}A). Similarly, inhibition of NUAK1 impaired the increase in spliced and exonic reads, although the effect was weaker than for PlaB ([Figure 5](#fig5){ref-type="fig"}A). Inspection of individual genes confirmed this observation ([Figure 5](#fig5){ref-type="fig"}B). Plotting the number of spliced reads per gene confirmed that the number of reads per gene increased during the chase in control (DMSO) cells but remained constant in BAY-880-treated cells and slightly decreased in PlaB-treated cells ([Figure 5](#fig5){ref-type="fig"}C).Figure 5NUAK1 Promotes Splicing and Transcription Termination(A) Left: definition of read categories; orange reads represent mature mRNA, yellow reads pre-mRNA. Right: percentage (average ± SD) of reads identified in the nascent RNA-seq analysis described in [Figure S5](#mmc1){ref-type="supplementary-material"}F.(B) Genome Browser tracks of 4sU-labeled RNA recovered from a pulse-chase experiment performed as described in [Figure S5](#mmc1){ref-type="supplementary-material"}F. For each chased (C) sample, three replicates (rep) are reported. Tracks were first normalized to overall reads, then exonic reads were electronically removed.(C) Kernel density plot of the number of reads harboring splice junctions (spliced reads; see A). Read counts were normalized to the number of exons per gene and the bandwidth was set to 0.3. Genes without spliced reads were removed. The mean over all replicates was plotted (DMSO, n = 16,257; BAY-880, n = 14,602; PlaB, n = 13,216; DMSO pulse, n = 13,249).(D) Gene sets identified by a GSEA on GO terms of genes showing splicing defects upon NUAK1 inhibition. Genes were ranked according to their splicing score. Splicing score was defined as the ratio between reads harboring splice junctions (spliced reads; see A) and pre-mRNA reads (reads falling into introns and intron-exon-spanning reads; yellow in A).(E) Top: kernel density plot of the termination score. The mean over all replicates was plotted and the bandwidth was set to 0.3 (DMSO, n = 18,782; BAY-880, n = 18,907; PlaB, n = 17,639; DMSO pulse, n = 16,342). Bottom: definition of termination score as reads in TES or TES + 20 kb/pre-mRNA reads, whereas pre-mRNA reads are defined as all reads falling into introns and intron-exon-spanning reads (i.e., yellow in A).(F) Genome Browser tracks of nascent RNA expression of a representative gene displaying termination readthrough. Tracks were generated as described in B (cumulative gene browser picture from three independent replicates).See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

The weaker effect of BAY-880 on overall splicing relative to that of PlaB is consistent with the lesser extent of BAY-880-mediated SF3B1 dephosphorylation ([Figures 4](#fig4){ref-type="fig"}I and [S5](#mmc1){ref-type="supplementary-material"}D). We reasoned that the role of NUAK1 might be restricted to a subset of genes, compared with the genome-wide effect of PlaB. We therefore performed a ranked sum gene set enrichment analysis (GSEA) ([@bib86]), ranking genes on the basis of a "splicing score" (defined as the ratio between spliced reads and pre-mRNA reads). Intriguingly, this analysis showed that the gene sets most strongly affected by NUAK1 inhibition were enriched for genes encoding proteins of the basic transcription machinery and nuclear structure ([Figure 5](#fig5){ref-type="fig"}D). Inspection of individual genes in the top enriched gene sets illustrated the strong effect of NUAK1 inhibition on intron retention of these mRNAs ([Figure S5](#mmc1){ref-type="supplementary-material"}F). The data suggest that expression of genes of the core transcriptional machinery is particularly sensitive to defects in NUAK1 activity.

Incubation of cells with BAY-880, but not with PlaB, also led to a strong increase in intergenic reads ([Figure 5](#fig5){ref-type="fig"}A). As described before, PNUTS also controls transcription termination ([@bib2], [@bib18]). Consistent with these observations, BAY-880 induced a marked increase of 3′ readthrough reads (TES-RT; positioned 3′ of the TES), representing inaccurately terminated transcripts ([Figures 5](#fig5){ref-type="fig"}E and 5F). We concluded that NUAK1 promotes both termination genome-wide and splicing of a specific subset of genes encoding proteins of the transcription machinery.

NUAK1 Controls a MYC-Sensitive Feedback Control of Transcriptional Elongation {#sec2.6}
-----------------------------------------------------------------------------

To understand whether the role of NUAK1 in splicing affects transcription, we performed both RNAPII ChIP-RX and 4sU pulse labeling of nascent RNA. In control cells, NUAK1 inhibition had no significant effect on RNAPII association with the TSS, the pause site, or the first exon-intron boundary ([Figures 6](#fig6){ref-type="fig"}A and 6B). In contrast, NUAK1 inhibition decreased overall RNAPII occupancy at the TES, suggesting that transcription elongation is impaired on many genes ([Figure 6](#fig6){ref-type="fig"}C). Consistent with this interpretation, we noted that overall nascent RNA synthesis, as tested by pulse labeling with 4sU, was significantly reduced upon NUAK1 inhibition ([Figures 7](#fig7){ref-type="fig"}A and 7B).Figure 6NUAK1 Controls RNAPII-Mediated Elongation in a MYC-Dependent Manner(A) RNAPII occupancy at three representative genes. Blue, Genome Browser tracks of RNAPII ChIP-RX upon treatment with 4 h 10 μM BAY-880 or DMSO in control cells (− MYC) or upon 20 h MYC-ER activation with 100 nM 4-OHT (+ MYC). Red, read difference between BAY-880 and DMSO samples.(B) Read density plots of RNAPII ChIP-RX analysis upon treatment with 4 h 10 μM BAY-880 or DMSO in control cells (− MYC) or upon 20 h MYC-ER activation with 100 nM 4-OHT (+ MYC). Plots are centered to transcription start site (TSS, left), RNAPII pause site (middle), or first exon-intron boundary (right).(C) Read density plots of RNAPII ChIP-RX analysis upon treatment with 4 h 10 μM BAY-880 or DMSO in control cells (− MYC) or upon MYC-ER activation (+ MYC). Plots are centered to transcription end site (TES). The shadow around tracks indicates SEM.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.Figure 7NUAK1 Affects Nascent RNA Synthesis, R-Loop Formation, and De-capping enzyme Recruitment in a MYC-Dependent Manner(A) Nascent RNA synthesis of two representative genes as determined by a 15 min pulse of 4sU incorporation (P). Blue, Genome Browser tracks of nascent RNA upon treatment with 4 h 10 μM BAY-880 or DMSO in control cells (− MYC) or upon MYC-ER activation (+ MYC; 20 h). Flowchart of experiment is shown in [Figure S5](#mmc1){ref-type="supplementary-material"}E. Tracks were generated as described in [Figure 5](#fig5){ref-type="fig"}B. Gray, ratio of reads in DMSO and BAY-880-treated samples.(B) Transcription start site (TSS)-centered read density plot (n = 6,133) of 4sU-labeled nascent RNA (15 min pulse; P) upon 2 h treatment with 10 μM BAY-880, 1 μM flavopiridol (FP), 1 μM NVP-2, or DMSO in control cells (− MYC) or upon MYC activation (+ MYC; 18 h). The shadow around tracks indicates SEM.(C) Top: Genome Browser track of a region of chromosome 7 showing DRIP(DNA-RNA-immunoprecipitation)-seq data in U2OS cells (GEO: [GSE115957](ncbi-geo:GSE115957){#intref0280}). Black bars, genes. Magnification shows detail of *ACTB* gene. Bottom: blue, Genome Browser tracks showing RNAPII occupancy at the *ACTB* gene locus upon treatment with 4 h 10 μM BAY-880 or DMSO in control cells (− MYC) or upon 20 h MYC activation with 100 nM 4-OHT (+ MYC). Red, read difference between BAY-880 and DMSO samples. Red arrows indicate the position of primers used for DRIP-qPCR (D).(D) Left: DRIP-qPCRs of U2OS MYC-ER cells treated with DMSO or 10 μM BAY-880 for 4 h and, where indicated, co-treated with 100 nM 4-OHT for 20 h (MYC). RNase H treatment and a negative region were used to test antibody specificity. Right: box blot summarizing all performed DRIP-qPCR analyses of U2OS MYC-ER cells treated as in the left plot. The plot shows average of 38 genetic loci ([Figure S7](#mmc1){ref-type="supplementary-material"}I) tested in three biologically independent experiments. All sets of data were normalized to their respective DMSO/-MYC condition. Dots represent values in the 10th to 90th percentiles. Wilcoxon matched-pairs signed rank tests were performed to compare the different conditions (n.s., not significant).(E) DCP1A ChIP of U2OS MYC-ER cells treated with DMSO or 10 μM BAY-880 for 4 h and, where indicated, co-treated with 100 nM 4-OHT for 20 h (MYC). All tested genetic loci reside at the TSS of the indicated genes. IgG ChIP and a negative region were used as antibody specificity controls. Neg ct, negative control (mean ± SD of technical triplicates of a representative experiment; n = 2).(F) Model summarizing our findings. For details, see text.See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.

To understand whether elevated levels of MYC influence these effects, we performed 4sU labeling and RNAPII ChIP-RX experiments on samples treated with BAY-880 16 h after the activation of a MYC-ER chimera. We first validated that induction of MYC did not alleviate the dependence of SF3B1 phosphorylation on NUAK1 ([Figure S6](#mmc1){ref-type="supplementary-material"}A), indicating that it did not alter the dependence of spliceosome activity on NUAK1. Analysis of nascent RNA synthesis by a pulse of 4sU showed that activation of MYC strongly enhanced nascent RNA synthesis ([Figures 7](#fig7){ref-type="fig"}A, 7B, and [S6](#mmc1){ref-type="supplementary-material"}B). In addition, activation of MYC strongly attenuated the decrease in nascent RNA synthesis caused by inhibition of NUAK1 on multiple genes ([Figure 7](#fig7){ref-type="fig"}A). Global analyses showed that MYC increased nascent RNA synthesis throughout the gene body in control cells; in contrast, the MYC-dependent increase was confined to promoter-proximal regions in the presence of BAY-880 ([Figure 7](#fig7){ref-type="fig"}B). Activation of MYC did not attenuate or override the block in transcription elongation caused by inhibition of CDK9 using either FP or NVP-2, demonstrating that MYC specifically overrides the inhibition of nascent RNA synthesis caused by BAY-880 ([Figures 7](#fig7){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}C). Remarkably and consistent with the 4sU data, RNAPII globally accumulated downstream of the TSS upon NUAK1 inhibition in cells with high levels of MYC ([Figures 6](#fig6){ref-type="fig"}A and 6B). Specifically, RNAPII accumulated at the pause site and both 5′ and 3′ of the first exon-intron boundary ([Figure 6](#fig6){ref-type="fig"}B). This localization closely paralleled the chromatin association of PNUTS (compare [Figure 3](#fig3){ref-type="fig"}D with [Figure 6](#fig6){ref-type="fig"}B; [Figure S6](#mmc1){ref-type="supplementary-material"}D). Comparison with published data describing the changes in RNAPII chromatin association in response to CDK9 inhibition ([@bib67]) showed that although inhibition of CDK9 causes an accumulation of RNAPII at the pause site, the peaks 5′ and 3′ of the first exon-intron boundary were observed only in response to inhibition of NUAK1 ([Figure S6](#mmc1){ref-type="supplementary-material"}E). We suggest that this accumulation reflects a delay or block in transcription elongation in response to a defect in mRNA splicing caused by inhibition of NUAK1.

Notably, RNA-seq showed that the accumulation of RNAPII upon NUAK1 inhibition in cells with high MYC levels was not paralleled by an increase in mRNA synthesis, arguing that the accumulating RNAPII is non-productive ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Consistently, RNAPII ChIP-RX showed that NUAK1 inhibition strongly suppressed RNAPII occupancy at the TES also in cells with active MYC ([Figure 6](#fig6){ref-type="fig"}C). Taken together, we concluded that inhibition of spliceosome assembly exerts a negative control on pause release or early steps of transcription elongation, which is overridden by elevated levels of MYC, leading to the accumulation of RNAPII at the first exon-intron boundary. The 4sU pulse-chase experiment also showed that inhibition of NUAK1 caused a striking increase in TES-RT/intergenic reads in both control and high-MYC cells, both on a global scale and when inspecting individual genes, consistent with the role of NUAK1 and PNUTs in termination ([Figures S7](#mmc1){ref-type="supplementary-material"}B and S7C).

To understand how inhibition of NUAK1 exerts the effects on early elongation, we reasoned that splicing defects can lead to the accumulation of stable hybrids of nascent RNA with DNA, termed R-loops ([@bib12]). To analyze this, we initially chose two genes that require NUAK1 for splicing, *ACTB* and *NCL* ([Figures 7](#fig7){ref-type="fig"}C and [S7](#mmc1){ref-type="supplementary-material"}D). Comparison with a recently published genome-wide sequencing dataset obtained from U2OS cells showed that R-loops are widespread over both genes ([@bib26]). Immunoprecipitations using a monoclonal antibody (S9.6) that specifically recognizes DNA-RNA hybrids showed that inhibition of NUAK1 caused R-loop accumulation at both *ACTB* and *NCL* gene loci ([Figure 7](#fig7){ref-type="fig"}D) and at multiple other genes bearing R-loops, as shown in the genome-wide analysis ([Figures 7](#fig7){ref-type="fig"}D and [S7](#mmc1){ref-type="supplementary-material"}E). Incubation of chromatin with RNase H, which selectively degrades DNA-RNA hybrids, removed the signal, confirming its specificity ([Figures 7](#fig7){ref-type="fig"}D and [S7](#mmc1){ref-type="supplementary-material"}E). In neuroblastoma cells, R-loop accumulation correlates with stalling of RNAPII and with recruitment of mRNA de-capping enzymes, which trigger transcription termination ([@bib7], [@bib38]). Consistent with these observations, NUAK1 inhibition led to recruitment of DCP1A, a core subunit of mRNA de-capping complexes, to several promoter-proximal regions that we tested ([Figure 7](#fig7){ref-type="fig"}E). Elevated MYC levels attenuated both R-loop accumulation and the recruitment of mRNA de-capping factors in response to NUAK1 inhibition ([Figures 7](#fig7){ref-type="fig"}D, 7E, and [S7](#mmc1){ref-type="supplementary-material"}E). We concluded that inhibition of NUAK1 and spliceosome activity induces R-loop accumulation and recruitment of mRNA de-capping factors and that MYC overrides this feedback-like control, indicating a model in which MYC drives transcriptional elongation in the absence of correctly assembled spliceosomes upon NUAK1 inhibition ([Figure 7](#fig7){ref-type="fig"}F).

Discussion {#sec3}
==========

Previous work has established that NUAK1 takes part in a trimeric complex with the catalytic subunit of PP1 and phosphorylates a regulatory subunit, MYPT1, in the cytoplasm ([@bib96]). Here, we extend this model by showing that a large fraction of NUAK1 is localized in the cell nucleus, associates with nuclear PP1 holoenzymes, and phosphorylates one of the major nuclear targeting subunits of PP1, PNUTS, at S313. Consistent with previous work that has implicated dephosphorylation by PP1 in controlling spliceosome activity, NUAK1 associates with spliceosomes ([@bib35], [@bib85], [@bib87]). Both PNUTS and NUAK1 are required for spliceosome activity and splicing of large sets of mRNAs. From these data, we propose a model in which PNUTS localizes to chromatin via its interaction with nascent RNA. As consequence, PNUTS comes into contact with chromatin-bound NUAK1, and its association with nascent RNA is stabilized by NUAK1-dependent phosphorylation. The stabilization locally inhibits PP1 activity toward spliceosomal proteins and enables spliceosome activation ([Figure 7](#fig7){ref-type="fig"}F). Inhibition of NUAK1 does not only impair spliceosome activity but also globally reduces nascent RNA synthesis and induces recruitment of mRNA de-capping factors. This suggests that regulation of PP1 activity also plays a critical role in coordinating transcription elongation with spliceosome activity. Previous observations have shown that elongating RNAPII associates with spliceosomes and accumulates over intron regions when spliceosome activity is perturbed ([@bib11], [@bib66]). Furthermore, the spliceosomal U1 RNP is part of a control mechanism that links pausing of RNAPII at the first stable nucleosome to premature polyadenylation-mediated termination ([@bib14]). Loss of PNUTS enhances phosphorylation of RNAPII at S5 in *Drosophila* embryos ([@bib17]). Although this may suggest a direct dephosphorylation of RNAPII by catalytically active PNUTS/PP1 holoenzymes in *Drosophila*, this increase may also be due to stalling of RNAPII (as seen in high-MYC cells) rather than to a direct role of PNUTS/PP1 in de-phosphorylating RNAPII. This interpretation is consistent with the observation that phosphorylation of S5 of RNAPII slows down elongation to promote spliceosome activity, whereas dephosphorylation of RNAPII enables rapid transcription of exonic sequences ([@bib65]). Our data argue that the localized inhibition of PP1 is a critical part of these checkpoint-like processes that link elongation to spliceosome activity.

Previous work has also established that a CDK9/PP1 switch is critical for transcription termination, and PP1 loss of function induces termination defects (e.g., readthrough transcription) ([@bib18], [@bib46], [@bib70]). Consistently, our and previously published ([@bib2], [@bib18]) observations implicate PNUTS in transcription termination. The data represented here extend this model to show that NUAK1 also affects the function of PNUTS in transcription termination.

Previous work both in tissue culture and *in vivo* has established that MYC-driven cells and tumors depend on NUAK1 for growth ([@bib58], [@bib62], [@bib72]). We did not observe any effect of NUAK1 depletion or inhibition on MYC phosphorylation at S62 and T58 or MYC stability or an association of NUAK1 with MYC, hence it is unlikely that the dependence of cells expressing deregulated MYC on NUAK1 reflects a previously described role of PNUTS in MYC turnover ([@bib29]). We show here that activation of MYC did not remove the requirement for NUAK1 in spliceosome activity. However, MYC strongly attenuated the reduction in nascent RNA synthesis, abolished the recruitment of de-capping complexes, and suppressed accumulation of R-loops upon NUAK1 inhibition at all loci we tested. Upon NUAK1 inhibition in cells expressing high MYC levels, RNAPII did not terminate transcription but accumulated both at the pause site and at the first exon-intron boundary. Notably, this increase in RNAPII association caused by NUAK1 inhibition was not mirrored by a corresponding increase in RNA synthesis, arguing that RNAPII accumulated in a non-productive form. Our data therefore suggest a model in which the perturbed spliceosome function upon NUAK1 inhibition induces RNAPII to terminate in cells with physiological MYC levels. In contrast, upon NUAK1 inhibition in MYC-driven tumor cells termination is suppressed and RNAPII is trapped in a form that is not involved in productive transcription ([Figure 7](#fig7){ref-type="fig"}F).

A strongly enhanced sensitivity of MYC-driven cells to a perturbation of the splicing machinery has been observed before in different biological systems; specifically, upregulation of the core spliceosome machinery is an essential step in MYC-driven lymphomagenesis, and MYC-driven lymphomas depend on PRMT5, an arginine methyltransferase that methylates spliceosomal proteins ([@bib50]). Furthermore, genetic or pharmacological inhibition of the spliceosome *in vivo* impairs survival and tumorigenicity of MYC-dependent breast cancers ([@bib40]). Finally, activation of MYC renders cells sensitive to inhibition of the CLK2 kinase, which has been linked to alternative splicing ([@bib43]). Similarly, the extreme sensitivity of MYC-transformed cells to depletion of glutamine ([@bib22]) is linked to the ability of MYC to drive transcriptional elongation in the absence of a sufficient nucleotide supply, leading to R-loop accumulation in the body of highly transcribed genes ([@bib28]). The notion that deregulated expression of MYC strongly sensitizes tumor cells toward a wide range of pro-apoptotic stimuli is considered a mechanism that protects from tumorigenesis ([@bib59]). Although the induction of individual target genes by MYC, such as BIM1, contributes to this sensitization ([@bib63]), the aggregate of available data argues that tumor cells that express elevated MYC levels ignore checkpoints that restrict early transcription and that the ensuing trapping of RNAPII is a common mechanism underlying these well-documented vulnerabilities of cells expressing oncogenic levels of MYC, for example by causing conflicts with the replication fork during S-phase that lead to double-strand breaks ([@bib37]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal anti-ACTBSigma-AldrichCat \#A5441 RRID:[AB_476744](nif-antibody:AB_476744){#intref0010} Lot: 026M4780VMouse monoclonal anti-VCLSigma-AldrichCat \#V9131 RRID:[AB_477629](nif-antibody:AB_477629){#intref0015} Lot: 036M4797VRabbit polyclonal anti-NUAK1 (used for immunofluorescence)Sigma-AldrichCat\# HPA057143 RRID:[AB_2683349](nif-antibody:AB_2683349){#intref0020} Lot: R80360Mouse monoclonal anti-FLAG M2Sigma-AldrichCat \#F3165 RRID:[AB_259529](nif-antibody:AB_259529){#intref0025} Lot: SLBT6752Mouse monoclonal anti-HA-tag (used for immunofluorescence)AbcamCat\# ab130275 RRID:[AB_11156884](nif-antibody:AB_11156884){#intref0030} Lot: GR320538-5Rabbit polyclonal anti-HA-tag (used for ChIP)AbcamCat\# ab9110 RRID:[AB_307019](nif-antibody:AB_307019){#intref0035}) Lot: GR3177614-4Rabbit monoclonal anti-MYC (clone Y69)AbcamCat\# ab32072 RRID:[AB_731658](nif-antibody:AB_731658){#intref0040} Lot: GR295111-34Rabbit polyclonal anti-phospho-Ser2-RNAPIIAbcamCat\# ab5095 RRID:[AB_304749](nif-antibody:AB_304749){#intref0045} Lot: GR3231908-1Rabbit polyclonal anti-TUBA1ASanta Cruz BiotechnologyCat\# sc-12462 RRID:[AB_2241125](nif-antibody:AB_2241125){#intref0050}Mouse monoclonal anti-PNUTS (used for immunoblotting)Santa Cruz BiotechnologyCat\# sc-271681 RRID:[AB_10708580](nif-antibody:AB_10708580){#intref0055} Lot: K1913Mouse monoclonal anti-PPP1CBSanta Cruz BiotechnologyCat\# sc-373782 RRID:[AB_10916703](nif-antibody:AB_10916703){#intref0060}Rabbit monoclonal anti-phospho-Thr313-SF3B1Cell Signaling TechnologyCat\# 25009 RRID:[AB_2798893](nif-antibody:AB_2798893){#intref0065} Lot: 1Rabbit monoclonal anti-HA-tag (used for immunoblotting)Cell Signaling TechnologyCat\# 3724 RRID:[AB_1549585](nif-antibody:AB_1549585){#intref0070} Lot: 7Rabbit monoclonal anti-MYPT1Cell Signaling TechnologyCat\# 8574 RRID:[AB_10998518](nif-antibody:AB_10998518){#intref0075} Lot: 1Rabbit polyclonal anti-NUAK1 (used for immunoblotting)Cell Signaling TechnologyCat\# 4458 RRID:[AB_2155859](nif-antibody:AB_2155859){#intref0080} Lot: 3Rabbit polyclonal anti-PNUTS (used for ChIP, immunofluorescence and immunoblotting)Bethyl LaboratoriesCat\# A300-439A RRID:[AB_420948](nif-antibody:AB_420948){#intref0085} Lot: 439A-3Mouse monoclonal anti-SF3B1MBL InternationalCat\# D221-3 RRID:[AB_592712](nif-antibody:AB_592712){#intref0090}Mouse monoclonal anti-RNAPIIMBL InternationalCat\# MABI0601 RRID:[AB_2728735](nif-antibody:AB_2728735){#intref0095}Mouse monoclonal anti-phospho-Ser5-RNAPIIBioLegendCat\# 904001 RRID:[AB_2565036](nif-antibody:AB_2565036){#intref0100}Mouse monoclonal anti-RNA-DNA hybrid (clone S9.6)KerafastCat\# ENH001 RRID:[AB_2687463](nif-antibody:AB_2687463){#intref0105}Mouse monoclonal anti-SC35BD PharMingenCat\# 556363 RRID:[AB_396388](nif-antibody:AB_396388){#intref0110}Rabbit polyclonal anti-phospho-Thr328-SF3B1Lührmann lab[@bib35]Rabbit polyclonal anti-phospho-Thr313-SF3B1Lührmann lab[@bib35]Rabbit polyclonal anti-phospho-Ser313-PNUTSRaised for this study (Davids Biotechnologie)N/AIRDye 800CW Donkey anti-Rabbit IgG (H + L)LI-COR BiosciencesCat\# 926-32213 RRID:[AB_621848](nif-antibody:AB_621848){#intref0115}IRDye 680RD Donkey anti-Mouse IgG (H + L)LI-COR BiosciencesCat\# 926-68072 RRID:[AB_10953628](nif-antibody:AB_10953628){#intref0120}Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488Thermo Fisher ScientificCat\# A-11008 RRID:[AB_143165](nif-antibody:AB_143165){#intref0125}Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 568Thermo Fisher ScientificCat\# A-11004 RRID:[AB_2534072](nif-antibody:AB_2534072){#intref0130}**Bacterial and Virus Strains**pBABE-puro (empty vector)This studyN/ApBABE-Nuak1-FLAG-NT-puroThis studyN/ApBABE-Nuak1-FLAG-CT-puroThis studyN/ApBABE-Nuak1-HA-NT-puroThis studyN/ApBABE-Nuak1-HA-CT-puroThis studyN/ApINDUCER11-NUAK1\#1This studyN/ApINDUCER11-NUAK1\#2This studyN/ApINDUCER11-NUAK1\#3This studyN/A**Chemicals, Peptides, and Recombinant Proteins**Stearyl-R8-KRPKGILKKRS peptideLifeTeinN/AFITC-Stearyl-R8 peptideLifeTeinCat\# LT12013BAY-880, IUPAC name 7-cyclopentyl-5-ethyl-2-(1H-pyrrol-2-yl)imidazo\[5,1-f\]\[1,2,4\]triazin-4(3H)-oneBayerEuropean Patent EP1399439B1, example 43NUAK1i (structurally related to BAY-880)BayerN/ACalyculin ASanta Cruz BiotechnologyCat\# sc-24000Pladienolide BSanta Cruz BiotechnologyCat\# sc-391691HTH-01-015SelleckchemCat\# S7318WZ4003SelleckchemCat\# S7317P276-00SelleckchemCat\# S8058LDC000067SelleckchemCat\# S7461NVP-2Tocris/Bio-TechneCat\# 6535/54-Thiouridine (4sU)Sigma-AldrichCat\# T4509BX795Sigma-AldrichCat\# 204001Okadaic acidSigma-AldrichCat\# 459620FlavopiridolSigma-AldrichCat\# F30554-hydroxytamoxifenSigma-AldrichCat\# H7904DoxycyclineSigma-AldrichCat\# D9891Cholera toxinSigma-AldrichCat\# C8052InsulinSigma-AldrichCat\# I9278HydrocortisoneSigma-AldrichCat\# H0396Protease inhibitor cocktailSigma-AldrichCat\# P8340Phosphatase inhibitor cocktail 2Sigma-AldrichCat\# P5726Phosphatase inhibitor cocktail 3Sigma-AldrichCat\# P0044Duolink *In Situ* PLA Probe Anti-Rabbit PLUSSigma-AldrichCat\# DUO92002Duolink *In Situ* PLA Probe Anti-Mouse MINUSSigma-AldrichCat\# DUO92004Duolink *In Situ* Detection Reagents RedSigma-AldrichCat\# DUO92008PuromycinInvivoGenCat\# ant-pr-1BenzonaseMerck MilliporeCat\#70664-3DAPIRothCat\# 6335.1RNase ARothCat\# 7156.1RNase HNEBCat\# M0297EcoRINEBCat\# R0101BamHINEBCat\# R0136BsrGINEBCat\# R0575HindIIINEBCat\# R0104SspINEBCat\# R0132XbaINEBCat\# R0145XhoINEBCat\# R0146Dynabead Protein AThermo Fisher ScientificCat\# 10002DDynabead Protein GThermo Fisher ScientificCat\# 10004DDynabeads MyOne Streptavidin T1Thermo Fisher ScientificCat\# 65601Dithiothreitol (DTT)Thermo Fisher ScientificCat\# 20291Lipofectamine 2000Thermo Fisher ScientificCat\# 11668019Lipofectamine RNAiMAXThermo Fisher ScientificCat\# 13778-150ibidi Mounting MediumIbidiCat\# 50001Odyssey Blocking Buffer in TBSLI-COR BiosciencesCat\# 927-50000peqGOLD TrifastPeqLab/WVRCat\# 30-2010**Critical Commercial Assays**Quant-iT PicoGreen dsDNA assayThermo Fisher ScientificCat\# P7589Quant-iT RiboGreen RNA Assay KitThermo Fisher ScientificCat\# R11490NEBNext ChIP-Seq Library Prep Master Mix Set for IlluminaNEBCat\# E6240NEBNext Ultra Directional RNA Library Prep Kit for IlluminaNEBCat\# E7420NEBNext Ultra II RNA Library Prep Kit for IlluminaNEBCat\# E7770NEBNext rRNA Depletion KitNEBCat\#E6310NEBNext Ultra II RNA Library Prep Kit for IlluminaNEBCat\# E7770RNeasy MinElute Cleanup KitQIAGENCat\#74204miRNeasy Mini KitQIAGENCat\# 217004NextSeq 500/550 High Output Kit v2IlluminaCat\# FC-404-2005**Deposited Data**Raw and analyzed dataThis studyGEO: [GSE129925](ncbi-geo:GSE129925){#intref0135}Raw and analyzed data[@bib91]GEO: [GSE44672](ncbi-geo:GSE44672){#intref0140}Raw and analyzed data[@bib26]GEO: [GSE115957](ncbi-geo:GSE115957){#intref0145}Raw and analyzed data[@bib67]GEO: [GSE89384](ncbi-geo:GSE89384){#intref0150}Human reference genome GRCh37/hg19Genome Reference Consortium<https://support.illumina.com/sequencing/sequencing_software/igenome.html>Raw images, proteomic dataThis studyMendeley Data <https://dx.doi.org/10.17632/rm56h9msym.1>**Experimental Models: Cell Lines**U2OSATCCRRID: CVCL_0042U2OS MYC-ER[@bib58]N/AHEK293TNATCCRRID: CVCL_UL49PlatEATCCRRID: CVCL_B488HeLaATCCRRID: CVCL_0030KPCSiveke labN/AIMR5Eggert labRRID: CVCL_1306NGPEggert labRRID: CVCL_2141SH-SY5YATCCRRID: CVCL_0019KellyEggert labRRID: CVCL_2092MCF10AATCCRRID: CVCL_0598SKNASATCCRRID: CVCL_1700NIH 3T3ATCCRRID: CVCL_0594**Oligonucleotides**Primers for ChIP, DRIP and qPCR: [Table S2](#mmc1){ref-type="supplementary-material"}This studyN/APrimers for cloning: [Table S3](#mmc1){ref-type="supplementary-material"}This studyN/APrimers for DRIP: [Table S4](#mmc1){ref-type="supplementary-material"}This studyN/AmirE_shNUAK1\#1: TGCTGTTGACAGTGAGCGC\
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Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Martin Eilers (<martin.eilers@biozentrum.uni-wuerzburg.de>). There are restrictions to the availability of BAY-880 due to the lack of an external centralized repository for its distribution and our need to maintain the stock. All other unique reagents generated in this study are available from the Lead Contact without restriction.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Employed cell lines {#sec4.3.1}

U2OS, HeLa, HEK293TN and PlatE human female; KPC and NIH 3T3 mouse male cell lines were cultured at 37°C (5% CO2) in DMEM (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich). SKNAS, SH-SY5Y, Kelly (female) and NGP, IMR-5 (male) human neuroblastoma cell lines were grown in RPMI-1640 (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum. MCF10A female human cell line was cultured in DMEM/F‐12 (Thermo Fisher Scientific) supplemented with 5% horse serum (Sigma-Aldrich), 100 μg/ml cholera toxin, 10 μg/ml insulin, 0.5 μg/ml hydrocortisone and 20 ng/ml EGF. All cell lines were verified by single tandem repeat profiling and routinely tested for mycoplasma contamination.

### Cell culture treatments {#sec4.3.2}

For siRNA transfection, 10 μl of 20 nM siRNA were mixed with 10 μl Lipofectamine RNAiMAX in 1 mL OptiMEM (Thermo Fisher Scientific). After 5 min incubation at RT, the mixture was added to cells overnight.

For plasmid transfection, FBS concentration was first adjusted to 2%. 10 μg DNA were then mixed with 10 μl Lipofectamine or polyethylenimine (PEI, Sigma-Aldrich) in 1 mL OptiMEM. After 20 min incubation at RT, the mixture was added to cells overnight.

For retroviral infection, PlatE cells were cultured till 80% confluence, then the FBS concentration was adjusted to 2%. 30 μg DNA were then mixed with 24 μl PEI in 1 mL OptiMEM. After 20 min incubation, the mixture was added to cells overnight. Cells were then cultured with 10% FBS for two days, collecting virus-containing supernatant every 24 h. Dead cells were removed from supernatant by employing 0.45 μm filters. Target cells were then cultured to 80% confluence and added 3 mL supernatant, 2 mL DMEM with 10% FBS and 4 μg/ml Polybrene (Sigma-Aldrich).

For lentiviral infection, HEK293TN cells were cultured to 80% confluence, then the FBS concentration was adjusted to 2%. 8 μg vector DNA, 8 μg psPAX2 and 2 μg pMD2.G were then mixed with 24 μl polyethylenimine in 1 mL OptiMEM. After 20 min incubation, the mixture was added to cells overnight. Cells were then cultured with 10% FBS for two days, collecting virus-containing supernatant every 12 h. Dead cells were removed from the supernatant by employing 0.45 μm filters. Target cells were then cultured to 30% confluence and added 500 μl supernatant, 5 mL DMEM with 10% FBS and 6 ug/ml Polybrene.

For peptide treatment, peptides were dissolved in water and added directly to cell culture medium. Peptides were designed with a stearyl-8xArg tail to facilitate cell penetration. GILK peptide sequence encompasses residues 395 to 407 within the GILK site \#1 of NUAK1 ([@bib96]).

BAY-880 -- originally described in the European Patent EP 1399439B1 -- was identified as a potent NUAK1 inhibitor by Bayer in an ultraHTS campaign screening 2.6 million compounds. The assay in the primary HTS used recombinant NUAK1 to phosphorylate a synthetic peptide. The phospho-readout was by TR-FRET. Primary hits were confirmed in an orthogonal ADP-Glo assay.

Method Details {#sec4.4}
--------------

### Immunofluorescence {#sec4.4.1}

Depending on the downstream application, cells were seeded in μ-Slide 8-well or 18-well chambers (Ibidi) or in 96-well μclear plates (Greiner). At the appropriate time point, cells were fixed with 4% PFA in PBS and permeabilized at least 20 min in ice-cold 100% methanol. Cells were then incubated at least 30 min in 5% BSA in PBS ("blocking solution"). First antibody in blocking solution was then added overnight. Wells were washed 3x with PBS, then added 1:1000 Alexa Fluor-conjugated second antibody in blocking solution for 1 h. 1:1000 DAPI in blocking solution was then added to wells were then added of for 5 min and washed 3x with PBS. Wells were added of ibidi Mounting Medium or PBS and stored at 4°C up to one week. Proximity ligation assays (PLA) were carried out using the Duolink *In Situ* Kit according to the manufacturer's protocol. Imaging was performed with a Nikon Eclipse-Ti confocal microscope (equipped with the NIS-elements AR 3.22.15 software) or with the Operetta High-Content Imaging System (Perkin Elmer).

### Cell fractionation {#sec4.4.2}

Plates were washed in ice-cold PBS (containing 1:1000 protease and phosphatase inhibitors) and cells were collected with a scraper and pelleted by 250 g centrifugation for 40 min. Pellets were resuspended in 1 mL sucrose buffer (10 mM HEPES pH 7.9, 0.34 M Sucrose, 3 mM CaCl~2~, 2 M magnesium acetate, 0.1 mM EDTA) with 0.5% NP-40 and incubated on a rotator for 10 min. Nuclei were then pelleted by 3900 g centrifugation for 20 min. The supernatant was collected as cytoplasmic fraction, while pellets were washed in 1 mL sucrose buffer and pelleted again by 3900 g centrifugation for 20 min. Pelleted nuclei were resuspended in 1 mL nucleoplasmic extraction buffer (20mM HEPES pH 7.9, 3 mM EDTA, 10% glycerol, 150 mM potassium acetate, 1.5 mM MgCl~2~), homogenized with a Dounce homogenizer and, after 40 min incubation, homogenized again. When applicable, samples were treated at this stage for 15 min with 20 μg RNase A at 37°C. Samples were then incubated 1 h with 25U benzonase and then centrifuged by 13000 rpm for 30 min. The supernatant was collected as nucleoplasmic fraction, while pellets were resuspended in 150 mM HEPES pH 7.9, 1.5 mM MgCl~2~, 150 mM potassium acetate with 2.5 U benzonase. After incubation for 30 min on a rotating wheel at RT, samples were pelleted and supernatants were collected as chromatin fraction.

### Immunoblotting {#sec4.4.3}

Whole-cell extracts were prepared using RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40). Briefly, plates were washed in ice-cold PBS (containing 1:1000 protease and phosphatase inhibitors) and cells were collected with a scraper and pelleted by 13000 rpm centrifugation for 5 min. Pellets were resuspended in RIPA buffer and incubated 30 min on ice. Tubes were then centrifuged at 13000 rpm for 5 min and supernatants were collected for further use. Protein lysates were quantified according to standard procedures (i.e., Bradford assay or bicinchoninic acid assay), separated employing Bis-Tris acrylamide gels and transferred on PVDF membranes (Merck-Millipore). Membranes were blocked 1 h with 20% Odyssey Blocking Buffer in TBS, incubated overnight with listed first antibodies in 20% Odyssey Blocking Buffer in TBS, washed 3x with TBS-T, incubated 1 h with IRDye 680RD or 800CW second antibodies, washed 3x with TBS-T and imaged and quantified with the Odyssey CLx Infrared Imaging System (LI-COR Biosciences).

### Co-immunoprecipitation {#sec4.4.4}

Plates were washed in ice-cold PBS (containing 1:1000 protease and phosphatase inhibitors) and cells were collected with a scraper and pelleted by 1500 rpm centrifugation for 10 min. Pellets were lysed in HEGN buffer (20 mM HEPES-KOH pH 7.8, 0.2 mM EDTA, 0.1% NP-40, 10 mM sodium pyrophosphate, 140 mM KCl, 10% glycerol, containing 1:1000 protease and phosphatase inhibitors), sonicated with a Branson sonifier 4x5 s at 20% amplitude and incubated 30 min on ice. Lysates were cleared upon repeated centrifugations and quantified according to standard procedures (i.e., Bradford assay of bicinchoninic acid assay). 1%--2% lysate was kept as input control. Unless otherwise noted, lysates were added 1 μg antibody (including a sample with 1 μg IgG control antibody, Sigma-Aldrich) and incubated 3-6 h on a rotating wheel at 4°C. 7.5 μl protein A/G Dynabeads per immunoprecipitation were washed three times in HEGN, then incubated with the lysate overnight. Beads were washed three times with HEGN, then resuspended in 60 μl 1X Lämmli buffer and processed for immunoblotting.

### Proteomic analysis of NUAK1 interactors {#sec4.4.5}

U2OS cells stably expressing N-terminal or C-terminal FLAG-tagged murine Nuak1 (or empty pBABE vector) were harvested and subjected to standard immunoprecipitation with minor modifications. Briefly, lysates were incubated overnight with anti-FLAG M2 magnetic beads (Sigma-Aldrich) and immunoprecipitates were eluted with 150ng/μl 3X FLAG peptide (Sigma-Aldrich) and acetone-precipitated. 5% of samples were loaded on Bis-Tris gels for checking actual FLAG-Nuak1 immunoprecipitation by immunoblotting or silver staining.

Acetone-precipitated samples were dissolved in NuPAGE LDS sample buffer (Thermo Fisher Scientific), reduced with 50 mM DTT at 70°C for 10 min and alkylated with 120 mM Iodoacetamide at room temperature for 20 min. Separation was performed on NuPAGE Novex 4%--12% Bis-Tris gels (Thermo Fisher Scientific) with MOPS buffer according to manufacturer's instructions. After washing 3x with water, gels were stained for 1h with Simply Blue Safe Stain (Thermo Fisher Scientific). After washing with water for 1 h, each gel lane was cut into 15 slices, destained with 30% acetonitrile in 0.1 M NH4HCO3 (pH 8), shrunk with 100% acetonitrile, and dried in a vacuum concentrator 5301 (Eppendorf). Samples were then digested with 0.1 μg trypsin per gel band overnight at 37°C in 0.1 M NH4HCO3 (pH 8). Peptides were extracted from the gel slices with 5% formic acid.

NanoLC-MS/MS analyses were performed on an LTQ-Orbitrap Velos Pro (Thermo Fisher Scientific) equipped with an EASY-Spray Ion Source and coupled to an EASY-nLC 1000 (Thermo Fisher Scientific). Peptides were loaded on a trapping column (2 cm x 75 μm ID. PepMap C18, 3 μm particles, 100 Å pore size) and separated on an EASY-Spray column (25 cm x 75 μm ID, PepMap C18, 2 μm particles, 100 Å pore size) with a 30-minute linear gradient from 3% to 30% acetonitrile and 0.1% formic acid. MS scans were acquired in the Orbitrap analyzer with a resolution of 30,000 at m/z 400, MS/MS scans were acquired in the Orbitrap analyzer with a resolution of 7,500 at m/z 400 using HCD fragmentation with 30% normalized collision energy. A TOP5 data-dependent MS/MS method was used; dynamic exclusion was applied with a repeat count of 1 and an exclusion duration of 30 s; singly charged precursors were excluded from selection. Minimum signal threshold for precursor selection was set to 50,000. Predictive AGC was used with AGC target a value of 1e6 for MS scans and 5e4 for MS/MS scans. Lock mass option was applied for internal calibration in all runs using background ions from protonated decamethylcyclopentasiloxane (m/z 371.10124).

Raw MS data files were analyzed with MaxQuant version 1.6.2.2 ([@bib19]). Database search was performed with Andromeda, which is integrated in the utilized version of MaxQuant. The search was performed against the UniProt Human database. Additionally, a database containing common contaminants was used. The search was performed with tryptic cleavage specificity with 3 allowed miscleavages. Protein identification was under control of the false-discovery rate (1% FDR on protein and peptide level). In addition to MaxQuant default settings, the search was performed against following variable modifications: Protein N-terminal acetylation, Gln to pyro-Glu formation (N-term. Gln) and oxidation (Met). Carbamidomethyl (Cys) was set as fixed modification. For protein quantitation, the LFQ intensities were used ([@bib21]). Proteins with less than two identified razor/unique peptides were dismissed.

Further data analysis was performed using R scripts developed in-house. LFQ intensities were used and missing LFQ intensities in the control samples were imputed with values close to the baseline. Data imputation was performed with values from a standard normal distribution with a mean of the 5% quantile of the combined log10-transformed LFQ intensities and a standard deviation of 0.1. For the identification of significantly co-immunoprecipitated proteins, mean log2 transformed protein ratio were calculated from the two replicate experiments and boxplot outliers were identified in intensity bins of at least 300 proteins. Log2 transformed protein ratios of CoIP versus control with values outside a 1.5x (potential) or 3x (extreme) interquartile range (IQR), respectively, were considered as significantly co-immunoprecipitated. GO term analyses of the dataset were performed with the web-available tool AmiGO ([@bib9]).

### Label-free phosphoproteomics {#sec4.4.6}

U2OS cells were treated for 2 h with 10 μM BAY-880, 10 μM HTH-01-015 or DMSO, then plates were washed in ice-cold PBS (containing 1:1000 protease and phosphatase inhibitors). Cells were then collected with a scraper, pelleted by 1500 rpm centrifugation for 10 min and flash-frozen in liquid nitrogen.

Samples were then digested in trifluoroacetic acid (TFA) and phosphopeptide-enriched according to the EasyPhos protocol with some changes ([@bib100]).

Pellets were first resuspended in GdmCl lysis buffer (6 M GdmCl, 100 mM Tris pH 8.5, 10 mM TCEP, 40 mM CAA). Samples were then added 50 mM DTT, shaken 10 min at 70°C, added 120 mM iodoacetamide and incubated 30 min in the dark. After adding 50 μl 1M ABC buffer, samples were added 4X acetone and proteins precipitated overnight. After centrifugation at 2000 g for 15 min, pellets were washed 3x with cold acetone and dried up. Pellets were then resuspended in 750 μl digestion buffer (10% TFA in 100mM ABC buffer) and sonified in a Bioruptor (5 cycles of 30sec). Samples were added 1:100 LysC and incubated 1 h at 37°C, then added 10 μg sequencing-grade modified trypsin (Promega) and incubated overnight at 37°C upon shaking. Digested samples were centrifuged at 16000 g for 20 min, then lyophilized overnight. Samples were dissolved in 2% ACN, 0.5% FA with the help 3x30 s Bioruptor cycles and 20 min shaking. Samples were then centrifuged for 5 min at 5000 g and cleaned up with Sep Pak C18 cartridges (Waters). 10 μl sample was collected for protein measurement, while the rest dried up lyophilized. Phosphopeptides were enriched with PhosphTio tips 3 mg/ 200 μl (GLSciences) and eluted in 150 μl 15% ACN, 5% ammoniumhydroxide before overnight lyophilization. Samples were redissolved in 100 μl 200 mM citric acid with 20 μl ACN and 1 μl formic acid shortly before NanoLC-MS/MS measurement.

NanoLC-MS/MS analyses were performed on an Orbitrap Fusion (Thermo Fisher Scientific) equipped with a PicoView Ion Source (New Objective) and coupled to an EASY-nLC 1000 (Thermo Fisher Scientific). Peptides were loaded on capillary columns (PicoFrit, 30 cm x 150 μm ID, New Objective) self-packed with ReproSil-Pur 120 C18-AQ, 1.9 μm (Dr. Maisch) and separated with a 90-minute linear gradient from 3% to 40% acetonitrile and 0.1% formic acid and a flow rate of 500 nl/min.

Both MS and MS/MS scans were acquired in the Orbitrap analyzer with a resolution of 60,000 for MS scans and 15,000 for MS/MS scans. HCD fragmentation with 35% normalized collision energy was applied. A Top Speed data-dependent MS/MS method with a fixed cycle time of 3 s was used. Dynamic exclusion was applied with a repeat count of 1 and an exclusion duration of 45 s; singly charged precursors were excluded from selection. Minimum signal threshold for precursor selection was set to 50,000. Predictive AGC was used with AGC a target value of 2e5 for MS scans and 5e4 for MS/MS scans. EASY-IC was used for internal calibration.

Raw MS data files were analyzed with MaxQuant version 1.5.7.4. Database search was performed with Andromeda, which is integrated in the utilized version of MaxQuant. The search was performed against the UniProt Human database. Additionally, a database containing common contaminants was used. The search was performed with tryptic cleavage specificity with 3 allowed miscleavages. Protein identification was under control of the false-discovery rate (1% FDR on protein and peptide level). In addition to MaxQuant default settings, the search was performed against following variable modifications: oxidation (Met), Gln to pyro-Glu formation (N-term. Gln) and Phospho (STY). Carbamidomethyl (Cys) was set as fixed modification. For protein quantitation, the LFQ intensities were used ([@bib21]). Proteins with less than two identified razor/unique peptides were dismissed. Intensities from MaxQuant Phospho (STY) table were used for relative quantitation of phosphorylation sites.

### Spike-in SILAC phosphoproteomics {#sec4.4.7}

U2OS cells were transfected overnight with siRNA targeting NUAK1 and grown for further 48 h after transfection start in standard DMEM. In parallel, SILAC reference cells were cultured with SILAC media (DMEM (-Lys, Arg, Gln), 10% dialyzed FBS, 1X LysH, 1XArgH, 1XGlnH) and grown until complete heavy label incorporation (\> 98%). At the moment of harvesting, cells were then collected with a scraper, pelleted by 1500 rpm centrifugation for 10 min and flash-frozen in liquid nitrogen.

Cell pellets were lysed with 8 M urea, 2 mM EDTA in 50 mM Tris HCl buffer, containing protease and phosphatase inhibitor cocktails. Cells were sonicated for 20 s with 2 pulses at 60% power (Sonoplus HD2070, Bandelin, Germany).

Protein concentration was determined by Bradford colorimetric assay. 1.75 mg of each sample was mixed with an equal amount of SILAC reference sample and proteins were reduced in DTT 2 mM for 30 min at 25°C and successively free cysteines were alkylated in 11 mM iodoacetamide for 20 min at room temperature in the darkness.

LysC digestion was performed by adding LysC (Wako) in a ratio 1:40 to the sample and incubating it for 16 h under gentle shaking at 30°C. After LysC digestion, the samples were diluted 3 times with 50 mM ammonium bicarbonate solution; afterward, trypsin was added in a 1:50 ratio and samples were incubated 4 h at 30°C. 15 mg of digested samples were desalted on STAGE Tips, dried and reconstituted to 25 μl of 0.5% acetic acid in water ([@bib64], [@bib78]).

The rest of the peptide mixtures was desalted on 3 mL SepPak C18 columns according to manufacturer's instructions and then dried under vacuum. Samples were dissolved before enrichment in buffer C.

Pre-packed 200 μl TiO2 Tips (GLSCience, Japan) were first washed with 20 μl of buffer B (80% ACN with 0.1% trifluoroacetic acid) and then 20 μl of buffer C. Then peptide sample was loaded on the tip and the beads washed with 20 μl of buffer C and 20 μl of buffer B.

For elution, 20 μl of 5% ammonium hydroxide in water were used. The eluate was acidified and purified STAGE Tips, dried and reconstituted to 7 μl of 0.5% acetic acid in water ([@bib78]).

5 μl were injected on a LC-MS/MS system (NanoLC-Ultra \[Eksigent\] and LTQ-Orbitrap Velos (Thermo Fisher Scientific), using a 240 min gradient ranging from 5% to 40% of solvent B (80% acetonitrile, 0.1% formic acid; solvent A 5 5% acetonitrile, 0.1% formic acid). For the chromatographic separation, a 20-cm-long capillary (75 mm inner diameter) was packed with 3 mm C18 beads (ReprosilPur C18 AQ, Dr. Maisch). On one end of the capillary a nanospray tip was generated using a laser puller (P-2000 Laser Based Micropipette Puller, Sutter Instruments), allowing fretless packing. The nanospray source was operated with a spray voltage of 2.1 kV and an ion transfer tube temperature of 260°C. Data were acquired in data dependent mode, with one survey MS scan in the Orbitrap mass analyzer (resolution 60,000 at m/z 400) followed by up to 20 MS\\MS scans in the ion trap on the most intense ions (intensity threshold, 500 counts). To improve the fragmentation of phosphopeptides, the multistage activation algorithm in the Xcalibur software was enabled for each MS/MS spectrum using the neutral loss values of 97.97, 48.99, 32.66 and 24.49 m/z units. Once selected for fragmentation, ions were excluded from further selection for 30 s, to increase new sequencing events.

Raw data was analyzed using the MaxQuant proteomics pipeline (v. 1.4.0.5) and the built-in Andromeda search engine ([@bib20]) with the Uniprot Human database. Carbamidomethylation of cysteines was chosen as fixed modification, oxidation of methionine and acetylation of N terminus were chosen as variable modifications. The search engine peptide assignments were filtered at 1% FDR and the feature match between runs was not enabled; second peptide feature was enabled, while other parameters were left as default. For SILAC samples, two ratio counts were set as threshold for quantification.

The MaxQuant output was further analyzed in Perseus v1.6.2.3 for Windows 10 ([@bib99]). Filtering was performed to exclude contaminants, reverse proteins, peptides with Andromeda score \< 40, peptides with localization probability ≤ 0.75, peptides with posterior error probability ≥ 0.05, and any peptide that did not present all valid values in at least one group of the dataset. Differentially phosphorylated sites were assessed by two-sided t test with permutation-based FDR truncation, using the default parameters, on the transformed log2 of the inverted ratio H/L normalized siRNA NUAK1 against the transformed log2 of the inverted ratio H/L normalized control. Gene Ontology (GO) terms ([@bib101]) represented in the differentially phosphorylated sites that presented *p* value ≤ 0.05 were evaluated with the in-built Fisher exact test. PPP1CA, PPP1CB, PPP1CC interactome curated in IntAct database ([@bib102]) were merged, filtered for human proteins and connections, and overlapped with differentially phosphorylated sites that presented *p* value ≤ 0.05 in R version 3.4.4 for macOS High Sierra ([@bib104]). The differentially phosphorylated sites, the GO terms, and PPP1C interactors were graphically represented using ggplot2 ([@bib105]) in R version 3.4.4 for macOS High Sierra ([@bib104]).

### Tandem Mass Tag (TMT) phosphoproteomics {#sec4.4.8}

U2OS cells were transfected overnight with a siRNA pool targeting *NUAK1* (or a non targeting control pool) and grown for further 48 h after transfection start in standard DMEM or treated 2 h with 10 μM BAY-880 (or DMSO) and then immediately washed with PBS to stop the treatment. Lysis buffer (2% SDS in 50 mM HEPES buffer, pH 8.5) was then immediately added to the plates and cells collected with a scraper. Lysates were incubated for 5 min at 95°C and subsequently placed on ice for 5 min. Finally, lysates were sonicated 30 s (5 s on/10 s off) with a Branson sonifier and protein concentration was determined using the BCA Protein Assay Kit (Thermo Scientific).

A total of 500 μg protein of each sample was precipitated using chloroform-methanol. Proteins were reconstituted in 8M urea. Reduction of Cys was performed using 10 mM DTT at 30°C for 30 min. The reaction was quenched by 50 mM chloroacetamide for 30 min. Samples were diluted to 1.6 M urea using 50 mM Tris-HCl (pH 8). Digestion was performed by adding trypsin (Promega) at a 1:50 enzyme-to-substrate ratio and incubated overnight at 30°C. Digests were acidified by adding formic acid to 0.5%, centrifuged to pellet insoluble matter, and desalted using tC18 RP solid-phase extraction cartridges (Waters Corp.; wash solvent: 0.1% formic acid (FA); elution solvent: 0.1% FA in 50% acetonitrile). Eluates were frozen at −80°C and dried by vacuum centrifugation.

Desalted peptides (100 μg per experimental condition) were reconstituted in 50 mM HEPES (pH8.5) and labeled by tandem mass tags (Thermo Fisher) as described ([@bib97]). TMT labeled samples were combined and enriched for phosphopeptides using immobilized metal affinity chromatography as described ([@bib79]). Subsequent high pH reversed phase fractionation of phosphopeptides was performed as described ([@bib80]). The resulting six phosphopeptide fractions were dried down and stored at −20°C until LC-MS measurement.

Nanoflow LC-MS/MS was performed on an Ultimate 3000 RSLCnano chromatography system coupled online to an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific). Phosphopeptides were reconstituted in 50 mM citric acid, 0.1% FA and loaded on a 75 μm x45cm analytical column (packed in-house with 3 μm C18 resin; Reprosil Gold, Dr. Maisch). Phosphopeptides were separated using a 90-min linear gradient from 4% to 32% LC solvent B (0.1% FA, 5% DMSO in ACN) at a flow rate of 300 nl/min. The mass spectrometer was operated in data dependent and positive ionization mode. MS1 spectra were recorded at a resolution of 60,000 using an automatic gain control (AGC) target value of 4e5 and a maximum injection time (maxIT) of 50 ms. For peptide identification, peptides were fragmented by collision-induced dissociation (CID) at 35% normalized collision energy with multistage activation in the ion trap and using an AGC target value of 5e4 and a maxIT of 60ms. Fragment ions were recorded at 30,000 resolution in the Orbitrap. For TMT quantification peptides were fragmented in the ion trap as above using an AGC of 1.2e5 and a maxIT of 120ms and fragment ions were subjected to synchronous precursor selection (SPS) and fragmented in the HCD cell at a normalized collision energy of 55% and the resulting MS3 spectrum was recorded in the Orbitrap at a resolution of 50,000.

Peptide identification and quantification were performed using MaxQuant (version 1.6.2.10) with its built-in search engine Andromeda. Tandem mass spectra were searched against the UniProt Human database supplemented with common contaminants. The search was performed with carbamidomethylated cysteine and TMT-modified lysine side chain and peptide N-termini as fixed modifications and oxidation (Met), N-terminal protein acetylation and phosphorylation (STY) as variable modifications. Results were filtered to 1% false discovery rate (FDR) on peptide spectrum match (PSM) level. The MaxQuant results was further analyzed in Perseus v1.6.1.1, also part of the MaxQuant software suite. Hits to the reverse and contaminant databased were removed. Relative abundances of phosphopeptides were determined using TMT reporter ion intensities from all PSMs and log2 transformed intensity value are reported throughout. Phosphopeptides were filtered for a minimum of 2 or 3 valid values in the four biological replicates. Differential phosphopeptide abundance was assessed by two-sided t tests with permutation-based FDR truncation, using default parameter for s0 (value of 0.1) and 1% FDR. Enrichment analysis of significantly regulated phosphopeptides for biological processes was performed using the Gene Ontology database. Only phosphosites with at least 3 valid values out of 4 biological replicates were considered.

### Chromatin IP (ChIP) {#sec4.4.9}

The ChIP protocol was performed as described before ([@bib38]) with minor modifications. Briefly, plates were added 1% formaldehyde (Roth) for 5-10 min to crosslink proteins to DNA, then added 1 M glycine (Roth) for 5 min and finally washed in ice-cold PBS (containing 1:1000 protease and phosphatase inhibitors). Cells were then collected with a scraper and pelleted by 1500 rpm centrifugation for 5 min at 4°C. Pellets were resuspended in lysis buffer I (5 mM PIPES pH 8, 85 mM KCl, 0.5% NP-40) for 20 min on ice and again collected by 1500 rpm centrifugation for 5 min at 4°C. Pellets were resuspended in lysis buffer II (50 mM HEPES pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS) for 10 min on ice and then sonified with either a Branson sonifier (20 min, 10 s on/30 s off, 25% amplitude) or a Covaris M220 instrument (30 min, duty factor 12, cycles/burst 220). 25 μl of sonified samples were decrosslinked (see below), DNA was purified with phenol/chloroform extraction and run in a 2% agarose gel to confirm sonication efficiency. 1% of sample was kept as input control.

15 μl each of protein A and G Dynabeads per immunoprecipitation were washed three times in 5% BSA in PBS (BSA-PBS), then added with 3 μl of antibody, then incubated overnight on a rotating wheel at 4°C. Beads were washed three times in BSA-PBS, then added to the samples and incubated overnight on a rotating wheel at 4°C. Immunoprecipitates were then washed 3x with washing buffer I (20mM Tris HCl pH 8, 150mM NaCl, 2mM EDTA, 0,1% SDS, 1% Triton X-100), 3x with washing buffer II (20mM Tris HCl pH 8, 500mM NaCl, 2mM EDTA, 0,1% SDS, 1% Triton X-100), 3x with ChIP wash buffer III (10mM Tris HCl pH 8, 250mM LiCl, 1mM EDTA, 1% NP40, 1% Deoxycholic acid sodium salt), incubating the samples 5 min on ice between each wash. Samples were then eluted by adding 2x 150-250 μl elution buffer (1% SDS, 50mM NaHCO~3~ in TE, pH 8.0) and incubated for 15 min on a rotating wheel \@RT. Samples were added 10 μg RNase A and incubated for 1 h at 37°C. Samples were then de-crosslinked by incubating overnight at 65°C and finally incubated with 2 μg proteinase K for 2 h at 45°C. Samples were then purified with phenol/chloroform extraction and quantified with qPCR. Where applicable, lysates were treated with 20 μg RNase A for 15 min at 37°C before incubating them with antibody-conjugated beads.

To perform ChIP followed by deep sequencing (ChIP-Seq), 100 million cells per condition were collected and processed as for a standard ChIP. Samples were then processed to build libraries for deep sequencing with the NEBNext ChIP-Seq Library Prep Master Mix Set for Illumina according to manufacturer's instruction. To perform ChIP-Seq with exogenous reference genome spike-in (ChIP-RX), 10 million mouse NIH 3T3 untreated cells were fixed, harvested, resuspended in lysis buffer I and added to every sample in lysis buffer I (i.e., from 100 million cells).

### DNA-RNA immunoprecipitation (DRIP) {#sec4.4.10}

The DRIP protocol was derived from ([@bib34]). Plates were washed in ice-cold PBS (containing 1:1000 protease and phosphatase inhibitors) and cells were collected with a scraper and pelleted by 1500 rpm centrifugation for 5 min. Pellets were resuspended in 2 mL lysis buffer (0.5% SDS, 5 μg proteinase K in TE, pH 8.0) and incubated on a rotating wheel overnight at 37°C. Genomic DNA was then extracted with phenol/chloroform purification and resuspended in 500 μl TE. Genomic DNA was digested with 60 U each of BsrGI, EcoRI, HindIII, SspI and XbaI by incubating overnight at 37°C. Aliquots of genomic DNA were pooled and additionally incubated with 60 U RNase H. Digested genomic DNA was then extracted with phenol/chloroform purification and resuspended in 1 mL ChIP binding buffer (10 mM sodium phosphate, 140 mM NaCl, 0.05% Triton X-100 in TE, pH 8.0). 10 μl sample was run in a 2% agarose gel to confirm restriction efficiency. 1% genomic DNA was collected as input control.

15 μl each of protein A and G Dynabeads per immunoprecipitation were washed three times in BSA-PBS, then added with 4 μg of anti-DNA-RNA hybrid antibody, then incubated overnight on a rotating wheel at 4°C. Beads were washed three times in BSA-PBS, then added to genomic DNA samples and incubated overnight on a rotating wheel at 4°C. Immunoprecipitates are then washed and eluted as for ChIP. Samples were finally incubated 2 h with 2 μg proteinase K, then purified with phenol/chloroform extraction and quantified with qPCR.

### Nascent RNA analysis by 4-thiouridine (4sU) labeling {#sec4.4.11}

U2OS cells were treated for 2 h with 10 μM BAY-880, 1 μM pladienolide B or DMSO, then added 200 μM 4sU for 15 min (pulse), then washed with PBS and treated in 4sU-free medium for additional 2 h (chase).

Treatment was stopped by adding Qiazol (QIAGEN). Total RNA was extracted using miRNAeasy kit according to manufacturer's instruction. 4sU-RNA was enriched and libraries were then prepared as previously described ([@bib3]). Briefly, 100 μg RNA was first biotinylated (EZ-Link Biotin-HPDP) with 2 h rotation at RT in biotin labeling buffer (10 mM Tris pH 7.4, 1 mM EDTA). Biotinylated RNA was cleaned up in MaXtract tubes, then pulled down using Dynabeads MyOne Streptavidin T1 beads for 15 min at 25°C with rotation. Beads were magnetically separated and repeatedly washed with wash buffer (2 M NaCl with 10 mM Tris pH 7.5, 1 mM EDTA and 0.1% Tween 20). 4sU-RNA was finally eluted using freshly prepared 100 mM DTT and cleaned using RNeasy MinElute Spin columns.

4sU-RNA was quantified with the RiboGreen Assay and processed for cDNA library preparation using NEBNext rRNA Depletion and Ultra RNA Library Prep kits for Illumina according to manufacturer's instructions.

### Directional RNA Sequencing {#sec4.4.12}

U2OS MYC-ER cells were induced with 4-OHT for 20 h with co-treatment of DMSO or 10 μM BAY-880 for the last 4 h. Treatment was stopped by adding Qiazol (QIAGEN), then lysates were homogenized by passing them 5 times through 0.6 mm needles. RNA extraction was performed with the miRNeasy Mini Kit according to manufacturer's instruction and using in-column DNase digestion. RNA quality was assessed employing a Fragment Analyzer (Agilent) and directional libraries were generated using the NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB) according to manufacturer's instructions.

### RNA extraction and quantitative PCR (qPCR) {#sec4.4.13}

RNA extraction was performed by resuspending cells in peqGOLD Trifast, then following manufacturer\'s instructions. cDNA was synthesized from 1 μg RNA adding M-MLV reverse transcriptase (Promega), random hexamers (Roche), dNTPs (Roth) and RiboLock RNase Inhibitor (Thermo Fisher Scientific).

qPCR was then performed with PowerUp SYBR Green Master Mix (Thermo Fisher Scientific) on a StepOnePlus thermocycler (Thermo Fisher Scientific) according to manufacturer's instructions and employing the listed primers ([Tables S2](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}).

### Cloning {#sec4.4.14}

#### FLAG- or HA-tagged NUAK1 vectors {#sec4.4.14.1}

A vector containing murine Nuak1 CDS was used as template for PCR with primers bearing HA or FLAG at amino- (NT) or carboxy-terminus (CT). All NT and CT primers contained respectively also a BamHI and a EcoRI restriction site to allow for downstream cloning in pBabe puro retroviral vectors ([Table S3](#mmc1){ref-type="supplementary-material"}).

#### Phospho mutant PNUTS vector {#sec4.4.14.2}

pcDNA5/TO-Flag-mPNUTS, a vector containing rat Ppp1r10 CDS (a kind gift of David Skalnik, Indiana University), was used as template for two PCRs (one for the coding region from ATG to S313, one for the one from S313 to stop codon) employing primers with mismatches on the S313 codon designed to generate a Ser to Ala, Asp or Glu mutant ([Table S3](#mmc1){ref-type="supplementary-material"}). Both PCR products (as well as pcDNA5/TO-Flag-mPNUTS) were used as templates for a subsequent PCR with primers bearing a BamHI restriction site at NT and a HA tag with a EcoRI restriction site at CT ([Table S3](#mmc1){ref-type="supplementary-material"}). BamHI-EcoRI restriction allowed for downstream cloning in pcDNA3 vector for further transfection.

#### Doxycycline-inducible shNUAK1 vectors {#sec4.4.14.3}

Three *NUAK1*-targeting sequences selected according to ([@bib30]) and included in the mirE backbone as previously described. The three constructs, named mirE shNUAK1\#1, \#2 and \#3, were then used as template for a PCR with primers bearing EcoRI and XhoI for subsequent cloning into the pINDUCER 11 lentiviral vector ([@bib61]). NUAK1-targeted sequences are TAAGGACAAAATTAAGGATGA (\#1), GCTGAAGAAATCCAAGAAAGA (\#2) and TAGGGATTTACTGGCATGGTA (\#3).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Bioinformatic analyses and statistical analyses {#sec4.5.1}

Fastq files were generated using Illumina's base calling software GenerateFASTQ v1.1.0.64 and overall sequencing quality was analyzed using the FastQC script.

For 4sU-seq, reads were mapped to the human genome (hg19) using Tophat v2.1.1 ([@bib49]) and Bowtie2 v2.3.2 ([@bib53]) using the parameters --g 1 --no-coverage-search. For 4sU-Seq including NVP-2/FP, the parameters were -N 1. Reads mapping to ribosomal rRNA (defined by UCSCs RepeatMasked table filtered for rRNA) were removed and all samples were normalized to the sample with the smallest number of mapped reads. Bedgraph files were generated with "bedtools genomecov" function after removal of reads falling in exons. Reads falling into different regions of genes (exons, the first intron of a gene, all introns, intron-spanning ("spliced"), exon-intron-overlapping, TES (defined as annotated transcriptional end site (TES) to TES+20kb), TES-overlapping ("TES-RT")) were filtered using the UCSC hg19 RefGene table. Reads falling into introns were normalized by the intron length and "spliced" reads were normalized for the number of exons per gene. For each gene and region analyzed, the mean from three replicates was calculated. The termination score is defined as: (TES reads + TES-RT reads) / pre-mRNA reads whereas pre-mRNA reads are all reads falling into introns and overlapping exon-intron-boundaries. Accordingly, the splicing score is defined as: spliced reads / pre-mRNA reads. Kernel density plots were calculated with the "density" function in R and a bandwidth of 0.3. 2D Kernel density plots were generated with the "smoothScatter" function in R and default settings. For gene set enrichment analysis ([@bib86]) the splicing score for each gene was calculated for each replicate separately and the analysis was performed with Signal2Noise ratio, 1000 permutations and the C5 and "Hallmark" gene sets from MSigDB v6.1 ([@bib57]).

For ChIP-seq, reads were mapped to the human genome (hg19) with bowtie v1.2 ([@bib54]) and default settings. Input samples for all biological conditions (DMSO, BAY-880, FP) were sequenced to a lower depth and combined after mapping. Duplicated reads were removed using "samtools rmdup" tool ([@bib56]) and samples were normalized to the sample with the smallest number of reads by randomly picking reads. For ChIP-RXseq, reads were independently mapped to hg19 and the murine spike-in genome (mm10) with bowtie v1.2 and default settings and a normalization factor was calculated as described previously ([@bib38]). Bedgraph files were generated with "bedtools genomecov" function and vizualized with the Integrated Genome Browser ([@bib31]). Peaks were called with MACS v1.4.2 ([@bib98]) using the input sample as control with a p value of 1e-8. Proximity to promoters (defined as TSS +-1kb) was analyzed with bedtools "closestBed" function and the UCSC hg19 RefSeq gene table. Average read density around the TSS (for all RefSeq listed genes), pause sites and first exon-boundary were calculated and plotted with deeptools ([@bib77]) using all genes with a PNUTS peak in the promoter. The mean of all analyzed genes is indicated by a solid line and the SEM is presented as shadow. For read density profiles, the mean is shown including the SEM as shadow. The pause site is defined by RNAPII peaks (condition EtOH/DMSO) called with MACS v1.4.2 (parameters: keep-dup 1, p value 1e-15,--call-subpeaks) without input control to avoid standard sequencing depth normalization. Peaks in the input were called independently with the same parameters and peaks present in the RNAPII and input sample were removed. Finally, RNAPII peaks were annotated to RNAPII TSS and all peaks in a region of TSS to TSS+250bp were selected as viewpoint for density plots of the pause site. ChIP-seq data for RNAPII were taken from [GSE44672](ncbi-geo:GSE44672){#intref0255} ([@bib91]) or [GSE89384](ncbi-geo:GSE89384){#intref0260} ([@bib67]) and analyzed as described above.

For RNA-seq, reads were aligned to the human genome (hg19) using Tophat v2.1.1 and Bowtie2 v2.3. using the parameters --g 1 --n 1--library-type fr-firststrand --no-coverage-search and samples were normalized to the number of mapped reads in the smallest sample. For gene expression analysis, reads per gene (Ensembl gene database) were counted with the "summarizeOverlaps" function from the R package "GenomicAlignments" using the "union"-mode and non- or weakly expressed genes were removed (mean read count over all samples \< 1).

In boxplots, the central line shows the median, the borders of the box indicate the first and third quartile and the whiskers extend to 1.5 of the interquartile range. Outliers are shown as black dots. P values comparing medians were calculated with an unpaired two-tailed Wilcoxon rank sum test.

Statistical significance throughout experimental conditions was addressed by employing the inherent test with the Prism software (GraphPad). P values \< 0.05 were considered statistically significant.

Data and Code Availability {#sec4.6}
--------------------------

RNA-, ChIP- and 4sU-seq data generated for this study are available at the Gene Expression Omnibus (GEO) under accession number [GSE129925](ncbi-geo:GSE129925){#intref0265}.

Raw pictures (immunostainings, immunoblotting) and proteomic data are available at the Mendeley Data repository at the address <http://dx.doi.org/10.17632/rm56h9msym.1>.
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